1
|
Liu WF, Hao L, Li ZY, Jin T, Sun Y, Yang YK, Li Y, Yang FJ, Yu F, Zhang Q, Niu XH. [Analysis of factors influencing the efficacy and prognosis of surgical treatment for primary malignant pelvic bone tumors]. Zhonghua Zhong Liu Za Zhi 2024; 46:344-353. [PMID: 38644270 DOI: 10.3760/cma.j.cn112152-20231024-00212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 04/23/2024]
Abstract
Objective: To analyze the prognostic factors and the influence of surgical margin to prognosis. Methods: A retrospective analysis was performed for 208 pelvic tumors who received surgical treatment from January 2000 to December 2017 in our instituition. Survival analysis was performed using the Kaplan-Meier method and Log rank test, and impact factor analysis was performed using Cox regression models. Results: There were 183 initial patients and 25 recurrent cases. According to Enneking staging, 110 cases were stage ⅠB and 98 cases were stage ⅡB. 19 lesions were in zone Ⅰ, 1 in zone Ⅱ, 15 in zone Ⅲ, 29 in zone Ⅰ+Ⅱ, 71 in zone Ⅱ+Ⅲ, 29 in zone Ⅰ+Ⅳ, 35 in zone Ⅰ+Ⅱ+Ⅲ, 3 in zone Ⅰ+Ⅱ+Ⅳ, and 6 in zone Ⅰ+Ⅱ+Ⅲ+Ⅳ. Surgical margins including Intralesional excision in 7 cases, contaminated margin in 21 cases, marginal resection in 67 cases, and wide resection in 113 cases. Local recurrence occurred in 37 cases (17.8%), 25 cases were performed by reoperation and 12 cases received amputation finally. The 5-year recurrence rate of marginal resection was higher than wide resection (P<0.05), and the recurrence-free survival rate of marginal resection was lower than wide resection (P<0.05). There was significant differences in recurrence rate and recurrence-free survival rate between R0 and R1 resection (P<0.05). 92 cases were not reconstructed and 116 cases were reconstructed after pelvic surgery. At the last follow-up, 63 patients (30.3%) died, and the 5-year, 10-year and 15-year survival rates were 70.4%, 66.8% and 61.3%, respectively. The 5-year survival rate of stage ⅠB and ⅡB tumor was 90.4% and 46.8%, respectively. There were 29 cases had postoperative wound complications (13.8%), 1 case with pelvic organ injury. The final function was evaluated in 132 patients, with an average MSTS score of 25.1±3.6. Cox multivariate analysis showed that surgical staging, R0/R1 margin and metastasis were independent prognostic factors for pelvic tumors. Conclusions: The safe surgical margin is the key factor for recurrence-free of pelvic tumor. The survival rate of stage ⅡB pelvic tumors was significantly lower than that of stage ⅠB tumors. Wound infection is the main postoperative complication. Surgical staging, R0/R1 margin and metastasis were independent prognostic factors of pelvic tumors.
Collapse
Affiliation(s)
- W F Liu
- Department of Orthopaedic Oncology Surgery, Beijing Ji Shui Tan Hospital, Capital Medical University,Beijing 100035, China
| | - L Hao
- Department of Orthopaedic Oncology Surgery, Beijing Ji Shui Tan Hospital, Capital Medical University,Beijing 100035, China
| | - Z Y Li
- Department of Orthopaedic Oncology Surgery, Beijing Ji Shui Tan Hospital, Capital Medical University,Beijing 100035, China
| | - T Jin
- Department of Orthopaedic Oncology Surgery, Beijing Ji Shui Tan Hospital, Capital Medical University,Beijing 100035, China
| | - Y Sun
- Department of Orthopaedic Oncology Surgery, Beijing Ji Shui Tan Hospital, Capital Medical University,Beijing 100035, China
| | - Y K Yang
- Department of Orthopaedic Oncology Surgery, Beijing Ji Shui Tan Hospital, Capital Medical University,Beijing 100035, China
| | - Y Li
- Department of Orthopaedic Oncology Surgery, Beijing Ji Shui Tan Hospital, Capital Medical University,Beijing 100035, China
| | - F J Yang
- Department of Orthopaedic Oncology Surgery, Beijing Ji Shui Tan Hospital, Capital Medical University,Beijing 100035, China
| | - F Yu
- Department of Orthopaedic Oncology Surgery, Beijing Ji Shui Tan Hospital, Capital Medical University,Beijing 100035, China
| | - Q Zhang
- Department of Orthopaedic Oncology Surgery, Beijing Ji Shui Tan Hospital, Capital Medical University,Beijing 100035, China
| | - X H Niu
- Department of Orthopaedic Oncology Surgery, Beijing Ji Shui Tan Hospital, Capital Medical University,Beijing 100035, China
| |
Collapse
|
2
|
Abbasi R, Ackermann M, Adams J, Agarwalla SK, Aguilar JA, Ahlers M, Alameddine JM, Amin NM, Andeen K, Anton G, Argüelles C, Ashida Y, Athanasiadou S, Axani SN, Bai X, Balagopal VA, Baricevic M, Barwick SW, Basu V, Bay R, Beatty JJ, Becker Tjus J, Beise J, Bellenghi C, Benning C, BenZvi S, Berley D, Bernardini E, Besson DZ, Blaufuss E, Blot S, Bontempo F, Book JY, Boscolo Meneguolo C, Böser S, Botner O, Böttcher J, Bourbeau E, Braun J, Brinson B, Brostean-Kaiser J, Burley RT, Busse RS, Butterfield D, Campana MA, Carloni K, Carnie-Bronca EG, Chattopadhyay S, Chau N, Chen C, Chen Z, Chirkin D, Choi S, Clark BA, Classen L, Coleman A, Collin GH, Connolly A, Conrad JM, Coppin P, Correa P, Cowen DF, Dave P, De Clercq C, DeLaunay JJ, Delgado D, Deng S, Deoskar K, Desai A, Desiati P, de Vries KD, de Wasseige G, DeYoung T, Diaz A, Díaz-Vélez JC, Dittmer M, Domi A, Dujmovic H, DuVernois MA, Ehrhardt T, Eller P, Ellinger E, El Mentawi S, Elsässer D, Engel R, Erpenbeck H, Evans J, Evenson PA, Fan KL, Fang K, Farrag K, Fazely AR, Feigl N, Fiedlschuster S, Fienberg AT, Finley C, Fischer L, Fox D, Franckowiak A, Fritz A, Fürst P, Gallagher J, Ganster E, Garcia A, Gerhardt L, Ghadimi A, Glaser C, Glauch T, Glüsenkamp T, Goehlke N, Gonzalez JG, Goswami S, Grant D, Gray SJ, Gries O, Griffin S, Griswold S, Groth KM, Günther C, Gutjahr P, Haack C, Hallgren A, Halliday R, Halve L, Halzen F, Hamdaoui H, Ha Minh M, Hanson K, Hardin J, Harnisch AA, Hatch P, Haungs A, Helbing K, Hellrung J, Henningsen F, Heuermann L, Heyer N, Hickford S, Hidvegi A, Hill C, Hill GC, Hoffman KD, Hori S, Hoshina K, Hou W, Huber T, Hultqvist K, Hünnefeld M, Hussain R, Hymon K, In S, Ishihara A, Jacquart M, Janik O, Jansson M, Japaridze GS, Jeong M, Jin M, Jones BJP, Kang D, Kang W, Kang X, Kappes A, Kappesser D, Kardum L, Karg T, Karl M, Karle A, Katz U, Kauer M, Kelley JL, Khatee Zathul A, Kheirandish A, Kiryluk J, Klein SR, Kochocki A, Koirala R, Kolanoski H, Kontrimas T, Köpke L, Kopper C, Koskinen DJ, Koundal P, Kovacevich M, Kowalski M, Kozynets T, Krishnamoorthi J, Kruiswijk K, Krupczak E, Kumar A, Kun E, Kurahashi N, Lad N, Lagunas Gualda C, Lamoureux M, Larson MJ, Latseva S, Lauber F, Lazar JP, Lee JW, Leonard DeHolton K, Leszczyńska A, Lincetto M, Liu QR, Liubarska M, Lohfink E, Love C, Lozano Mariscal CJ, Lucarelli F, Luszczak W, Lyu Y, Madsen J, Mahn KBM, Makino Y, Manao E, Mancina S, Marie Sainte W, Mariş IC, Marka S, Marka Z, Marsee M, Martinez-Soler I, Maruyama R, Mayhew F, McElroy T, McNally F, Mead JV, Meagher K, Mechbal S, Medina A, Meier M, Merckx Y, Merten L, Micallef J, Mitchell J, Montaruli T, Moore RW, Morii Y, Morse R, Moulai M, Mukherjee T, Naab R, Nagai R, Nakos M, Naumann U, Necker J, Negi A, Neumann M, Niederhausen H, Nisa MU, Noell A, Novikov A, Nowicki SC, Obertacke Pollmann A, O'Dell V, Oehler M, Oeyen B, Olivas A, Orsoe R, Osborn J, O'Sullivan E, Pandya H, Pankova DV, Park N, Parker GK, Paudel EN, Paul L, Pérez de Los Heros C, Peterson J, Philippen S, Pizzuto A, Plum M, Pontén A, Popovych Y, Prado Rodriguez M, Pries B, Procter-Murphy R, Przybylski GT, Raab C, Rack-Helleis J, Rawlins K, Rechav Z, Rehman A, Reichherzer P, Renzi G, Resconi E, Reusch S, Rhode W, Riedel B, Rifaie A, Roberts EJ, Robertson S, Rodan S, Roellinghoff G, Rongen M, Rott C, Ruhe T, Ruohan L, Ryckbosch D, Safa I, Saffer J, Salazar-Gallegos D, Sampathkumar P, Sanchez Herrera SE, Sandrock A, Santander M, Sarkar S, Sarkar S, Savelberg J, Savina P, Schaufel M, Schieler H, Schindler S, Schlickmann L, Schlüter B, Schlüter F, Schmeisser N, Schmidt T, Schneider J, Schröder FG, Schumacher L, Schwefer G, Sclafani S, Seckel D, Seikh M, Seunarine S, Shah R, Sharma A, Shefali S, Shimizu N, Silva M, Skrzypek B, Smithers B, Snihur R, Soedingrekso J, Søgaard A, Soldin D, Soldin P, Sommani G, Spannfellner C, Spiczak GM, Stamatikos M, Stanev T, Stezelberger T, Stürwald T, Stuttard T, Sullivan GW, Taboada I, Ter-Antonyan S, Thiesmeyer M, Thompson WG, Thwaites J, Tilav S, Tollefson K, Tönnis C, Toscano S, Tosi D, Trettin A, Tung CF, Turcotte R, Twagirayezu JP, Ty B, Unland Elorrieta MA, Upadhyay AK, Upshaw K, Valtonen-Mattila N, Vandenbroucke J, van Eijndhoven N, Vannerom D, van Santen J, Vara J, Veitch-Michaelis J, Venugopal M, Vereecken M, Verpoest S, Veske D, Vijai A, Walck C, Weaver C, Weigel P, Weindl A, Weldert J, Wen AY, Wendt C, Werthebach J, Weyrauch M, Whitehorn N, Wiebusch CH, Willey N, Williams DR, Witthaus L, Wolf A, Wolf M, Wrede G, Xu XW, Yanez JP, Yildizci E, Yoshida S, Young R, Yu F, Yu S, Zhang Z, Zhelnin P, Zilberman P, Zimmerman M. Observation of Seven Astrophysical Tau Neutrino Candidates with IceCube. Phys Rev Lett 2024; 132:151001. [PMID: 38682982 DOI: 10.1103/physrevlett.132.151001] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/22/2023] [Revised: 02/15/2024] [Accepted: 02/29/2024] [Indexed: 05/01/2024]
Abstract
We report on a measurement of astrophysical tau neutrinos with 9.7 yr of IceCube data. Using convolutional neural networks trained on images derived from simulated events, seven candidate ν_{τ} events were found with visible energies ranging from roughly 20 TeV to 1 PeV and a median expected parent ν_{τ} energy of about 200 TeV. Considering backgrounds from astrophysical and atmospheric neutrinos, and muons from π^{±}/K^{±} decays in atmospheric air showers, we obtain a total estimated background of about 0.5 events, dominated by non-ν_{τ} astrophysical neutrinos. Thus, we rule out the absence of astrophysical ν_{τ} at the 5σ level. The measured astrophysical ν_{τ} flux is consistent with expectations based on previously published IceCube astrophysical neutrino flux measurements and neutrino oscillations.
Collapse
Affiliation(s)
- R Abbasi
- Department of Physics, Loyola University Chicago, Chicago, Illinois 60660, USA
| | - M Ackermann
- Deutsches Elektronen-Synchrotron DESY, Platanenallee 6, 15738 Zeuthen, Germany
| | - J Adams
- Department of Physics and Astronomy, University of Canterbury, Private Bag 4800, Christchurch, New Zealand
| | - S K Agarwalla
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - J A Aguilar
- Université Libre de Bruxelles, Science Faculty CP230, B-1050 Brussels, Belgium
| | - M Ahlers
- Niels Bohr Institute, University of Copenhagen, DK-2100 Copenhagen, Denmark
| | - J M Alameddine
- Department of Physics, TU Dortmund University, D-44221 Dortmund, Germany
| | - N M Amin
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - K Andeen
- Department of Physics, Marquette University, Milwaukee, Wisconsin 53201, USA
| | - G Anton
- Erlangen Centre for Astroparticle Physics, Friedrich-Alexander-Universität Erlangen-Nürnberg, D-91058 Erlangen, Germany
| | - C Argüelles
- Department of Physics and Laboratory for Particle Physics and Cosmology, Harvard University, Cambridge, Massachusetts 02138, USA
| | - Y Ashida
- Department of Physics and Astronomy, University of Utah, Salt Lake City, Utah 84112, USA
| | - S Athanasiadou
- Deutsches Elektronen-Synchrotron DESY, Platanenallee 6, 15738 Zeuthen, Germany
| | - S N Axani
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - X Bai
- Physics Department, South Dakota School of Mines and Technology, Rapid City, South Dakota 57701, USA
| | - V A Balagopal
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - M Baricevic
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - S W Barwick
- Department of Physics and Astronomy, University of California, Irvine, California 92697, USA
| | - V Basu
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - R Bay
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - J J Beatty
- Department of Astronomy, Ohio State University, Columbus, Ohio 43210, USA
- Department of Physics and Center for Cosmology and Astro-Particle Physics, Ohio State University, Columbus, Ohio 43210, USA
| | - J Becker Tjus
- Fakultät für Physik & Astronomie, Ruhr-Universität Bochum, D-44780 Bochum, Germany
| | - J Beise
- Department of Physics and Astronomy, Uppsala University, Box 516, S-75120 Uppsala, Sweden
| | - C Bellenghi
- Physik-department, Technische Universität München, D-85748 Garching, Germany
| | - C Benning
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - S BenZvi
- Department of Physics and Astronomy, University of Rochester, Rochester, New York 14627, USA
| | - D Berley
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | - E Bernardini
- Dipartimento di Fisica e Astronomia Galileo Galilei, Università Degli Studi di Padova, 35122 Padova PD, Italy
| | - D Z Besson
- Department of Physics and Astronomy, University of Kansas, Lawrence, Kansas 66045, USA
| | - E Blaufuss
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | - S Blot
- Deutsches Elektronen-Synchrotron DESY, Platanenallee 6, 15738 Zeuthen, Germany
| | - F Bontempo
- Karlsruhe Institute of Technology, Institute for Astroparticle Physics, D-76021 Karlsruhe, Germany
| | - J Y Book
- Department of Physics and Laboratory for Particle Physics and Cosmology, Harvard University, Cambridge, Massachusetts 02138, USA
| | - C Boscolo Meneguolo
- Dipartimento di Fisica e Astronomia Galileo Galilei, Università Degli Studi di Padova, 35122 Padova PD, Italy
| | - S Böser
- Institute of Physics, University of Mainz, Staudinger Weg 7, D-55099 Mainz, Germany
| | - O Botner
- Department of Physics and Astronomy, Uppsala University, Box 516, S-75120 Uppsala, Sweden
| | - J Böttcher
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - E Bourbeau
- Niels Bohr Institute, University of Copenhagen, DK-2100 Copenhagen, Denmark
| | - J Braun
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - B Brinson
- School of Physics and Center for Relativistic Astrophysics, Georgia Institute of Technology, Atlanta, Georgia 30332, USA
| | - J Brostean-Kaiser
- Deutsches Elektronen-Synchrotron DESY, Platanenallee 6, 15738 Zeuthen, Germany
| | - R T Burley
- Department of Physics, University of Adelaide, Adelaide, 5005, Australia
| | - R S Busse
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, D-48149 Münster, Germany
| | - D Butterfield
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - M A Campana
- Department of Physics, Drexel University, 3141 Chestnut Street, Philadelphia, Pennsylvania 19104, USA
| | - K Carloni
- Department of Physics and Laboratory for Particle Physics and Cosmology, Harvard University, Cambridge, Massachusetts 02138, USA
| | - E G Carnie-Bronca
- Department of Physics, University of Adelaide, Adelaide, 5005, Australia
| | - S Chattopadhyay
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - N Chau
- Université Libre de Bruxelles, Science Faculty CP230, B-1050 Brussels, Belgium
| | - C Chen
- School of Physics and Center for Relativistic Astrophysics, Georgia Institute of Technology, Atlanta, Georgia 30332, USA
| | - Z Chen
- Department of Physics and Astronomy, Stony Brook University, Stony Brook, New York 11794-3800, USA
| | - D Chirkin
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - S Choi
- Department of Physics, Sungkyunkwan University, Suwon 16419, Korea
| | - B A Clark
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | - L Classen
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, D-48149 Münster, Germany
| | - A Coleman
- Department of Physics and Astronomy, Uppsala University, Box 516, S-75120 Uppsala, Sweden
| | - G H Collin
- Department of Physics, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - A Connolly
- Department of Astronomy, Ohio State University, Columbus, Ohio 43210, USA
- Department of Physics and Center for Cosmology and Astro-Particle Physics, Ohio State University, Columbus, Ohio 43210, USA
| | - J M Conrad
- Department of Physics, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - P Coppin
- Vrije Universiteit Brussel (VUB), Dienst ELEM, B-1050 Brussels, Belgium
| | - P Correa
- Vrije Universiteit Brussel (VUB), Dienst ELEM, B-1050 Brussels, Belgium
| | - D F Cowen
- Department of Astronomy and Astrophysics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - P Dave
- School of Physics and Center for Relativistic Astrophysics, Georgia Institute of Technology, Atlanta, Georgia 30332, USA
| | - C De Clercq
- Vrije Universiteit Brussel (VUB), Dienst ELEM, B-1050 Brussels, Belgium
| | - J J DeLaunay
- Department of Physics and Astronomy, University of Alabama, Tuscaloosa, Alabama 35487, USA
| | - D Delgado
- Department of Physics and Laboratory for Particle Physics and Cosmology, Harvard University, Cambridge, Massachusetts 02138, USA
| | - S Deng
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - K Deoskar
- Oskar Klein Centre and Department of Physics, Stockholm University, SE-10691 Stockholm, Sweden
| | - A Desai
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - P Desiati
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - K D de Vries
- Vrije Universiteit Brussel (VUB), Dienst ELEM, B-1050 Brussels, Belgium
| | - G de Wasseige
- Centre for Cosmology, Particle Physics and Phenomenology-CP3, Université catholique de Louvain, Louvain-la-Neuve, Belgium
| | - T DeYoung
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - A Diaz
- Department of Physics, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - J C Díaz-Vélez
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - M Dittmer
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, D-48149 Münster, Germany
| | - A Domi
- Erlangen Centre for Astroparticle Physics, Friedrich-Alexander-Universität Erlangen-Nürnberg, D-91058 Erlangen, Germany
| | - H Dujmovic
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - M A DuVernois
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - T Ehrhardt
- Institute of Physics, University of Mainz, Staudinger Weg 7, D-55099 Mainz, Germany
| | - P Eller
- Physik-department, Technische Universität München, D-85748 Garching, Germany
| | - E Ellinger
- Department of Physics, University of Wuppertal, D-42119 Wuppertal, Germany
| | - S El Mentawi
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - D Elsässer
- Department of Physics, TU Dortmund University, D-44221 Dortmund, Germany
| | - R Engel
- Karlsruhe Institute of Technology, Institute for Astroparticle Physics, D-76021 Karlsruhe, Germany
- Karlsruhe Institute of Technology, Institute of Experimental Particle Physics, D-76021 Karlsruhe, Germany
| | - H Erpenbeck
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - J Evans
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | - P A Evenson
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - K L Fan
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | - K Fang
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - K Farrag
- Department of Physics and The International Center for Hadron Astrophysics, Chiba University, Chiba 263-8522, Japan
| | - A R Fazely
- Department of Physics, Southern University, Baton Rouge, Louisiana 70813, USA
| | - N Feigl
- Institut für Physik, Humboldt-Universität zu Berlin, D-12489 Berlin, Germany
| | - S Fiedlschuster
- Erlangen Centre for Astroparticle Physics, Friedrich-Alexander-Universität Erlangen-Nürnberg, D-91058 Erlangen, Germany
| | - A T Fienberg
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - C Finley
- Oskar Klein Centre and Department of Physics, Stockholm University, SE-10691 Stockholm, Sweden
| | - L Fischer
- Deutsches Elektronen-Synchrotron DESY, Platanenallee 6, 15738 Zeuthen, Germany
| | - D Fox
- Department of Astronomy and Astrophysics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - A Franckowiak
- Fakultät für Physik & Astronomie, Ruhr-Universität Bochum, D-44780 Bochum, Germany
| | - A Fritz
- Institute of Physics, University of Mainz, Staudinger Weg 7, D-55099 Mainz, Germany
| | - P Fürst
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - J Gallagher
- Department of Astronomy, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - E Ganster
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - A Garcia
- Department of Physics and Laboratory for Particle Physics and Cosmology, Harvard University, Cambridge, Massachusetts 02138, USA
| | - L Gerhardt
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - A Ghadimi
- Department of Physics and Astronomy, University of Alabama, Tuscaloosa, Alabama 35487, USA
| | - C Glaser
- Department of Physics and Astronomy, Uppsala University, Box 516, S-75120 Uppsala, Sweden
| | - T Glauch
- Physik-department, Technische Universität München, D-85748 Garching, Germany
| | - T Glüsenkamp
- Erlangen Centre for Astroparticle Physics, Friedrich-Alexander-Universität Erlangen-Nürnberg, D-91058 Erlangen, Germany
- Department of Physics and Astronomy, Uppsala University, Box 516, S-75120 Uppsala, Sweden
| | - N Goehlke
- Karlsruhe Institute of Technology, Institute of Experimental Particle Physics, D-76021 Karlsruhe, Germany
| | - J G Gonzalez
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - S Goswami
- Department of Physics and Astronomy, University of Alabama, Tuscaloosa, Alabama 35487, USA
| | - D Grant
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - S J Gray
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | - O Gries
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - S Griffin
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - S Griswold
- Department of Physics and Astronomy, University of Rochester, Rochester, New York 14627, USA
| | - K M Groth
- Niels Bohr Institute, University of Copenhagen, DK-2100 Copenhagen, Denmark
| | - C Günther
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - P Gutjahr
- Department of Physics, TU Dortmund University, D-44221 Dortmund, Germany
| | - C Haack
- Erlangen Centre for Astroparticle Physics, Friedrich-Alexander-Universität Erlangen-Nürnberg, D-91058 Erlangen, Germany
| | - A Hallgren
- Department of Physics and Astronomy, Uppsala University, Box 516, S-75120 Uppsala, Sweden
| | - R Halliday
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - L Halve
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - F Halzen
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - H Hamdaoui
- Department of Physics and Astronomy, Stony Brook University, Stony Brook, New York 11794-3800, USA
| | - M Ha Minh
- Physik-department, Technische Universität München, D-85748 Garching, Germany
| | - K Hanson
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - J Hardin
- Department of Physics, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - A A Harnisch
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - P Hatch
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - A Haungs
- Karlsruhe Institute of Technology, Institute for Astroparticle Physics, D-76021 Karlsruhe, Germany
| | - K Helbing
- Department of Physics, University of Wuppertal, D-42119 Wuppertal, Germany
| | - J Hellrung
- Fakultät für Physik & Astronomie, Ruhr-Universität Bochum, D-44780 Bochum, Germany
| | - F Henningsen
- Physik-department, Technische Universität München, D-85748 Garching, Germany
| | - L Heuermann
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - N Heyer
- Department of Physics and Astronomy, Uppsala University, Box 516, S-75120 Uppsala, Sweden
| | - S Hickford
- Department of Physics, University of Wuppertal, D-42119 Wuppertal, Germany
| | - A Hidvegi
- Oskar Klein Centre and Department of Physics, Stockholm University, SE-10691 Stockholm, Sweden
| | - C Hill
- Department of Physics and The International Center for Hadron Astrophysics, Chiba University, Chiba 263-8522, Japan
| | - G C Hill
- Department of Physics, University of Adelaide, Adelaide, 5005, Australia
| | - K D Hoffman
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | - S Hori
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - K Hoshina
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - W Hou
- Karlsruhe Institute of Technology, Institute for Astroparticle Physics, D-76021 Karlsruhe, Germany
| | - T Huber
- Karlsruhe Institute of Technology, Institute for Astroparticle Physics, D-76021 Karlsruhe, Germany
| | - K Hultqvist
- Oskar Klein Centre and Department of Physics, Stockholm University, SE-10691 Stockholm, Sweden
| | - M Hünnefeld
- Department of Physics, TU Dortmund University, D-44221 Dortmund, Germany
| | - R Hussain
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - K Hymon
- Department of Physics, TU Dortmund University, D-44221 Dortmund, Germany
| | - S In
- Department of Physics, Sungkyunkwan University, Suwon 16419, Korea
| | - A Ishihara
- Department of Physics and The International Center for Hadron Astrophysics, Chiba University, Chiba 263-8522, Japan
| | - M Jacquart
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - O Janik
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - M Jansson
- Oskar Klein Centre and Department of Physics, Stockholm University, SE-10691 Stockholm, Sweden
| | - G S Japaridze
- CTSPS, Clark-Atlanta University, Atlanta, Georgia 30314, USA
| | - M Jeong
- Department of Physics, Sungkyunkwan University, Suwon 16419, Korea
| | - M Jin
- Department of Physics and Laboratory for Particle Physics and Cosmology, Harvard University, Cambridge, Massachusetts 02138, USA
| | - B J P Jones
- Department of Physics, University of Texas at Arlington, 502 Yates St., Science Hall Rm 108, Box 19059, Arlington, Texas 76019, USA
| | - D Kang
- Karlsruhe Institute of Technology, Institute for Astroparticle Physics, D-76021 Karlsruhe, Germany
| | - W Kang
- Department of Physics, Sungkyunkwan University, Suwon 16419, Korea
| | - X Kang
- Department of Physics, Drexel University, 3141 Chestnut Street, Philadelphia, Pennsylvania 19104, USA
| | - A Kappes
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, D-48149 Münster, Germany
| | - D Kappesser
- Institute of Physics, University of Mainz, Staudinger Weg 7, D-55099 Mainz, Germany
| | - L Kardum
- Department of Physics, TU Dortmund University, D-44221 Dortmund, Germany
| | - T Karg
- Deutsches Elektronen-Synchrotron DESY, Platanenallee 6, 15738 Zeuthen, Germany
| | - M Karl
- Physik-department, Technische Universität München, D-85748 Garching, Germany
| | - A Karle
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - U Katz
- Erlangen Centre for Astroparticle Physics, Friedrich-Alexander-Universität Erlangen-Nürnberg, D-91058 Erlangen, Germany
| | - M Kauer
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - J L Kelley
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - A Khatee Zathul
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - A Kheirandish
- Department of Physics & Astronomy, University of Nevada, Las Vegas, Nevada, 89154, USA
- Nevada Center for Astrophysics, University of Nevada, Las Vegas, Nevada 89154, USA
| | - J Kiryluk
- Department of Physics and Astronomy, Stony Brook University, Stony Brook, New York 11794-3800, USA
| | - S R Klein
- Department of Physics, University of California, Berkeley, California 94720, USA
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - A Kochocki
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - R Koirala
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - H Kolanoski
- Institut für Physik, Humboldt-Universität zu Berlin, D-12489 Berlin, Germany
| | - T Kontrimas
- Physik-department, Technische Universität München, D-85748 Garching, Germany
| | - L Köpke
- Institute of Physics, University of Mainz, Staudinger Weg 7, D-55099 Mainz, Germany
| | - C Kopper
- Erlangen Centre for Astroparticle Physics, Friedrich-Alexander-Universität Erlangen-Nürnberg, D-91058 Erlangen, Germany
| | - D J Koskinen
- Niels Bohr Institute, University of Copenhagen, DK-2100 Copenhagen, Denmark
| | - P Koundal
- Karlsruhe Institute of Technology, Institute for Astroparticle Physics, D-76021 Karlsruhe, Germany
| | - M Kovacevich
- Department of Physics, Drexel University, 3141 Chestnut Street, Philadelphia, Pennsylvania 19104, USA
| | - M Kowalski
- Institut für Physik, Humboldt-Universität zu Berlin, D-12489 Berlin, Germany
- Deutsches Elektronen-Synchrotron DESY, Platanenallee 6, 15738 Zeuthen, Germany
| | - T Kozynets
- Niels Bohr Institute, University of Copenhagen, DK-2100 Copenhagen, Denmark
| | - J Krishnamoorthi
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - K Kruiswijk
- Centre for Cosmology, Particle Physics and Phenomenology-CP3, Université catholique de Louvain, Louvain-la-Neuve, Belgium
| | - E Krupczak
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - A Kumar
- Deutsches Elektronen-Synchrotron DESY, Platanenallee 6, 15738 Zeuthen, Germany
| | - E Kun
- Fakultät für Physik & Astronomie, Ruhr-Universität Bochum, D-44780 Bochum, Germany
| | - N Kurahashi
- Department of Physics, Drexel University, 3141 Chestnut Street, Philadelphia, Pennsylvania 19104, USA
| | - N Lad
- Deutsches Elektronen-Synchrotron DESY, Platanenallee 6, 15738 Zeuthen, Germany
| | - C Lagunas Gualda
- Deutsches Elektronen-Synchrotron DESY, Platanenallee 6, 15738 Zeuthen, Germany
| | - M Lamoureux
- Centre for Cosmology, Particle Physics and Phenomenology-CP3, Université catholique de Louvain, Louvain-la-Neuve, Belgium
| | - M J Larson
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | - S Latseva
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - F Lauber
- Department of Physics, University of Wuppertal, D-42119 Wuppertal, Germany
| | - J P Lazar
- Department of Physics and Laboratory for Particle Physics and Cosmology, Harvard University, Cambridge, Massachusetts 02138, USA
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - J W Lee
- Department of Physics, Sungkyunkwan University, Suwon 16419, Korea
| | - K Leonard DeHolton
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - A Leszczyńska
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - M Lincetto
- Fakultät für Physik & Astronomie, Ruhr-Universität Bochum, D-44780 Bochum, Germany
| | - Q R Liu
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - M Liubarska
- Department of Physics, University of Alberta, Edmonton, Alberta, Canada T6G 2E1
| | - E Lohfink
- Institute of Physics, University of Mainz, Staudinger Weg 7, D-55099 Mainz, Germany
| | - C Love
- Department of Physics, Drexel University, 3141 Chestnut Street, Philadelphia, Pennsylvania 19104, USA
| | - C J Lozano Mariscal
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, D-48149 Münster, Germany
| | - F Lucarelli
- Département de physique nucléaire et corpusculaire, Université de Genève, CH-1211 Genève, Switzerland
| | - W Luszczak
- Department of Astronomy, Ohio State University, Columbus, Ohio 43210, USA
- Department of Physics and Center for Cosmology and Astro-Particle Physics, Ohio State University, Columbus, Ohio 43210, USA
| | - Y Lyu
- Department of Physics, University of California, Berkeley, California 94720, USA
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - J Madsen
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - K B M Mahn
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - Y Makino
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - E Manao
- Physik-department, Technische Universität München, D-85748 Garching, Germany
| | - S Mancina
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
- Dipartimento di Fisica e Astronomia Galileo Galilei, Università Degli Studi di Padova, 35122 Padova PD, Italy
| | - W Marie Sainte
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - I C Mariş
- Université Libre de Bruxelles, Science Faculty CP230, B-1050 Brussels, Belgium
| | - S Marka
- Columbia Astrophysics and Nevis Laboratories, Columbia University, New York, New York 10027, USA
| | - Z Marka
- Columbia Astrophysics and Nevis Laboratories, Columbia University, New York, New York 10027, USA
| | - M Marsee
- Department of Physics and Astronomy, University of Alabama, Tuscaloosa, Alabama 35487, USA
| | - I Martinez-Soler
- Department of Physics and Laboratory for Particle Physics and Cosmology, Harvard University, Cambridge, Massachusetts 02138, USA
| | - R Maruyama
- Department of Physics, Yale University, New Haven, Connecticut 06520, USA
| | - F Mayhew
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - T McElroy
- Department of Physics, University of Alberta, Edmonton, Alberta, Canada T6G 2E1
| | - F McNally
- Department of Physics, Mercer University, Macon, Georgia 31207-0001, USA
| | - J V Mead
- Niels Bohr Institute, University of Copenhagen, DK-2100 Copenhagen, Denmark
| | - K Meagher
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - S Mechbal
- Deutsches Elektronen-Synchrotron DESY, Platanenallee 6, 15738 Zeuthen, Germany
| | - A Medina
- Department of Physics and Center for Cosmology and Astro-Particle Physics, Ohio State University, Columbus, Ohio 43210, USA
| | - M Meier
- Department of Physics and The International Center for Hadron Astrophysics, Chiba University, Chiba 263-8522, Japan
| | - Y Merckx
- Vrije Universiteit Brussel (VUB), Dienst ELEM, B-1050 Brussels, Belgium
| | - L Merten
- Fakultät für Physik & Astronomie, Ruhr-Universität Bochum, D-44780 Bochum, Germany
| | - J Micallef
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - J Mitchell
- Department of Physics, Southern University, Baton Rouge, Louisiana 70813, USA
| | - T Montaruli
- Département de physique nucléaire et corpusculaire, Université de Genève, CH-1211 Genève, Switzerland
| | - R W Moore
- Department of Physics, University of Alberta, Edmonton, Alberta, Canada T6G 2E1
| | - Y Morii
- Department of Physics and The International Center for Hadron Astrophysics, Chiba University, Chiba 263-8522, Japan
| | - R Morse
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - M Moulai
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - T Mukherjee
- Karlsruhe Institute of Technology, Institute for Astroparticle Physics, D-76021 Karlsruhe, Germany
| | - R Naab
- Deutsches Elektronen-Synchrotron DESY, Platanenallee 6, 15738 Zeuthen, Germany
| | - R Nagai
- Department of Physics and The International Center for Hadron Astrophysics, Chiba University, Chiba 263-8522, Japan
| | - M Nakos
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - U Naumann
- Department of Physics, University of Wuppertal, D-42119 Wuppertal, Germany
| | - J Necker
- Deutsches Elektronen-Synchrotron DESY, Platanenallee 6, 15738 Zeuthen, Germany
| | - A Negi
- Department of Physics, University of Texas at Arlington, 502 Yates St., Science Hall Rm 108, Box 19059, Arlington, Texas 76019, USA
| | - M Neumann
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, D-48149 Münster, Germany
| | - H Niederhausen
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - M U Nisa
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - A Noell
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - A Novikov
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - S C Nowicki
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - A Obertacke Pollmann
- Department of Physics and The International Center for Hadron Astrophysics, Chiba University, Chiba 263-8522, Japan
| | - V O'Dell
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - M Oehler
- Karlsruhe Institute of Technology, Institute for Astroparticle Physics, D-76021 Karlsruhe, Germany
| | - B Oeyen
- Department of Physics and Astronomy, University of Gent, B-9000 Gent, Belgium
| | - A Olivas
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | - R Orsoe
- Physik-department, Technische Universität München, D-85748 Garching, Germany
| | - J Osborn
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - E O'Sullivan
- Department of Physics and Astronomy, Uppsala University, Box 516, S-75120 Uppsala, Sweden
| | - H Pandya
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - D V Pankova
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - N Park
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - G K Parker
- Department of Physics, University of Texas at Arlington, 502 Yates St., Science Hall Rm 108, Box 19059, Arlington, Texas 76019, USA
| | - E N Paudel
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - L Paul
- Department of Physics, Marquette University, Milwaukee, Wisconsin 53201, USA
- Physics Department, South Dakota School of Mines and Technology, Rapid City, South Dakota 57701, USA
| | - C Pérez de Los Heros
- Department of Physics and Astronomy, Uppsala University, Box 516, S-75120 Uppsala, Sweden
| | - J Peterson
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - S Philippen
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - A Pizzuto
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - M Plum
- Physics Department, South Dakota School of Mines and Technology, Rapid City, South Dakota 57701, USA
| | - A Pontén
- Department of Physics and Astronomy, Uppsala University, Box 516, S-75120 Uppsala, Sweden
| | - Y Popovych
- Institute of Physics, University of Mainz, Staudinger Weg 7, D-55099 Mainz, Germany
| | - M Prado Rodriguez
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - B Pries
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - R Procter-Murphy
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | - G T Przybylski
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - C Raab
- Centre for Cosmology, Particle Physics and Phenomenology-CP3, Université catholique de Louvain, Louvain-la-Neuve, Belgium
| | - J Rack-Helleis
- Institute of Physics, University of Mainz, Staudinger Weg 7, D-55099 Mainz, Germany
| | - K Rawlins
- Department of Physics and Astronomy, University of Alaska Anchorage, 3211 Providence Dr., Anchorage, Alaska 99508, USA
| | - Z Rechav
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - A Rehman
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - P Reichherzer
- Fakultät für Physik & Astronomie, Ruhr-Universität Bochum, D-44780 Bochum, Germany
| | - G Renzi
- Université Libre de Bruxelles, Science Faculty CP230, B-1050 Brussels, Belgium
| | - E Resconi
- Physik-department, Technische Universität München, D-85748 Garching, Germany
| | - S Reusch
- Deutsches Elektronen-Synchrotron DESY, Platanenallee 6, 15738 Zeuthen, Germany
| | - W Rhode
- Department of Physics, TU Dortmund University, D-44221 Dortmund, Germany
| | - B Riedel
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - A Rifaie
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - E J Roberts
- Department of Physics, University of Adelaide, Adelaide, 5005, Australia
| | - S Robertson
- Department of Physics, University of California, Berkeley, California 94720, USA
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - S Rodan
- Department of Physics, Sungkyunkwan University, Suwon 16419, Korea
| | - G Roellinghoff
- Department of Physics, Sungkyunkwan University, Suwon 16419, Korea
| | - M Rongen
- Erlangen Centre for Astroparticle Physics, Friedrich-Alexander-Universität Erlangen-Nürnberg, D-91058 Erlangen, Germany
| | - C Rott
- Department of Physics and Astronomy, University of Utah, Salt Lake City, Utah 84112, USA
- Department of Physics, Sungkyunkwan University, Suwon 16419, Korea
| | - T Ruhe
- Department of Physics, TU Dortmund University, D-44221 Dortmund, Germany
| | - L Ruohan
- Physik-department, Technische Universität München, D-85748 Garching, Germany
| | - D Ryckbosch
- Department of Physics and Astronomy, University of Gent, B-9000 Gent, Belgium
| | - I Safa
- Department of Physics and Laboratory for Particle Physics and Cosmology, Harvard University, Cambridge, Massachusetts 02138, USA
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - J Saffer
- Karlsruhe Institute of Technology, Institute of Experimental Particle Physics, D-76021 Karlsruhe, Germany
| | - D Salazar-Gallegos
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - P Sampathkumar
- Karlsruhe Institute of Technology, Institute for Astroparticle Physics, D-76021 Karlsruhe, Germany
| | - S E Sanchez Herrera
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - A Sandrock
- Department of Physics, University of Wuppertal, D-42119 Wuppertal, Germany
| | - M Santander
- Department of Physics and Astronomy, University of Alabama, Tuscaloosa, Alabama 35487, USA
| | - S Sarkar
- Department of Physics, University of Alberta, Edmonton, Alberta, Canada T6G 2E1
| | - S Sarkar
- Department of Physics, University of Oxford, Parks Road, Oxford OX1 3PU, United Kingdom
| | - J Savelberg
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - P Savina
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - M Schaufel
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - H Schieler
- Karlsruhe Institute of Technology, Institute for Astroparticle Physics, D-76021 Karlsruhe, Germany
| | - S Schindler
- Erlangen Centre for Astroparticle Physics, Friedrich-Alexander-Universität Erlangen-Nürnberg, D-91058 Erlangen, Germany
| | - L Schlickmann
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - B Schlüter
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, D-48149 Münster, Germany
| | - F Schlüter
- Université Libre de Bruxelles, Science Faculty CP230, B-1050 Brussels, Belgium
| | - N Schmeisser
- Department of Physics, University of Wuppertal, D-42119 Wuppertal, Germany
| | - T Schmidt
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | - J Schneider
- Erlangen Centre for Astroparticle Physics, Friedrich-Alexander-Universität Erlangen-Nürnberg, D-91058 Erlangen, Germany
| | - F G Schröder
- Karlsruhe Institute of Technology, Institute for Astroparticle Physics, D-76021 Karlsruhe, Germany
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - L Schumacher
- Erlangen Centre for Astroparticle Physics, Friedrich-Alexander-Universität Erlangen-Nürnberg, D-91058 Erlangen, Germany
| | - G Schwefer
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - S Sclafani
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | - D Seckel
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - M Seikh
- Department of Physics and Astronomy, University of Kansas, Lawrence, Kansas 66045, USA
| | - S Seunarine
- Department of Physics, University of Wisconsin, River Falls, Wisconsin 54022, USA
| | - R Shah
- Department of Physics, Drexel University, 3141 Chestnut Street, Philadelphia, Pennsylvania 19104, USA
| | - A Sharma
- Department of Physics and Astronomy, Uppsala University, Box 516, S-75120 Uppsala, Sweden
| | - S Shefali
- Karlsruhe Institute of Technology, Institute of Experimental Particle Physics, D-76021 Karlsruhe, Germany
| | - N Shimizu
- Department of Physics and The International Center for Hadron Astrophysics, Chiba University, Chiba 263-8522, Japan
| | - M Silva
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - B Skrzypek
- Department of Physics and Laboratory for Particle Physics and Cosmology, Harvard University, Cambridge, Massachusetts 02138, USA
| | - B Smithers
- Department of Physics, University of Texas at Arlington, 502 Yates St., Science Hall Rm 108, Box 19059, Arlington, Texas 76019, USA
| | - R Snihur
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - J Soedingrekso
- Department of Physics, TU Dortmund University, D-44221 Dortmund, Germany
| | - A Søgaard
- Niels Bohr Institute, University of Copenhagen, DK-2100 Copenhagen, Denmark
| | - D Soldin
- Karlsruhe Institute of Technology, Institute of Experimental Particle Physics, D-76021 Karlsruhe, Germany
| | - P Soldin
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - G Sommani
- Fakultät für Physik & Astronomie, Ruhr-Universität Bochum, D-44780 Bochum, Germany
| | - C Spannfellner
- Physik-department, Technische Universität München, D-85748 Garching, Germany
| | - G M Spiczak
- Department of Physics, University of Wisconsin, River Falls, Wisconsin 54022, USA
| | - M Stamatikos
- Department of Physics and Center for Cosmology and Astro-Particle Physics, Ohio State University, Columbus, Ohio 43210, USA
| | - T Stanev
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - T Stezelberger
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - T Stürwald
- Department of Physics, University of Wuppertal, D-42119 Wuppertal, Germany
| | - T Stuttard
- Niels Bohr Institute, University of Copenhagen, DK-2100 Copenhagen, Denmark
| | - G W Sullivan
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | - I Taboada
- School of Physics and Center for Relativistic Astrophysics, Georgia Institute of Technology, Atlanta, Georgia 30332, USA
| | - S Ter-Antonyan
- Department of Physics, Southern University, Baton Rouge, Louisiana 70813, USA
| | - M Thiesmeyer
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - W G Thompson
- Department of Physics and Laboratory for Particle Physics and Cosmology, Harvard University, Cambridge, Massachusetts 02138, USA
| | - J Thwaites
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - S Tilav
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - K Tollefson
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - C Tönnis
- Department of Physics, Sungkyunkwan University, Suwon 16419, Korea
| | - S Toscano
- Université Libre de Bruxelles, Science Faculty CP230, B-1050 Brussels, Belgium
| | - D Tosi
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - A Trettin
- Deutsches Elektronen-Synchrotron DESY, Platanenallee 6, 15738 Zeuthen, Germany
| | - C F Tung
- School of Physics and Center for Relativistic Astrophysics, Georgia Institute of Technology, Atlanta, Georgia 30332, USA
| | - R Turcotte
- Karlsruhe Institute of Technology, Institute for Astroparticle Physics, D-76021 Karlsruhe, Germany
| | - J P Twagirayezu
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - B Ty
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - M A Unland Elorrieta
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, D-48149 Münster, Germany
| | - A K Upadhyay
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - K Upshaw
- Department of Physics, Southern University, Baton Rouge, Louisiana 70813, USA
| | - N Valtonen-Mattila
- Department of Physics and Astronomy, Uppsala University, Box 516, S-75120 Uppsala, Sweden
| | - J Vandenbroucke
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - N van Eijndhoven
- Vrije Universiteit Brussel (VUB), Dienst ELEM, B-1050 Brussels, Belgium
| | - D Vannerom
- Department of Physics, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - J van Santen
- Deutsches Elektronen-Synchrotron DESY, Platanenallee 6, 15738 Zeuthen, Germany
| | - J Vara
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, D-48149 Münster, Germany
| | - J Veitch-Michaelis
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - M Venugopal
- Karlsruhe Institute of Technology, Institute for Astroparticle Physics, D-76021 Karlsruhe, Germany
| | - M Vereecken
- Centre for Cosmology, Particle Physics and Phenomenology-CP3, Université catholique de Louvain, Louvain-la-Neuve, Belgium
| | - S Verpoest
- Bartol Research Institute and Department of Physics and Astronomy, University of Delaware, Newark, Delaware 19716, USA
| | - D Veske
- Columbia Astrophysics and Nevis Laboratories, Columbia University, New York, New York 10027, USA
| | - A Vijai
- Department of Physics, University of Maryland, College Park, Maryland 20742, USA
| | - C Walck
- Oskar Klein Centre and Department of Physics, Stockholm University, SE-10691 Stockholm, Sweden
| | - C Weaver
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - P Weigel
- Department of Physics, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - A Weindl
- Karlsruhe Institute of Technology, Institute for Astroparticle Physics, D-76021 Karlsruhe, Germany
| | - J Weldert
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - A Y Wen
- Department of Physics and Laboratory for Particle Physics and Cosmology, Harvard University, Cambridge, Massachusetts 02138, USA
| | - C Wendt
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - J Werthebach
- Department of Physics, TU Dortmund University, D-44221 Dortmund, Germany
| | - M Weyrauch
- Karlsruhe Institute of Technology, Institute for Astroparticle Physics, D-76021 Karlsruhe, Germany
| | - N Whitehorn
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - C H Wiebusch
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - N Willey
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - D R Williams
- Department of Physics and Astronomy, University of Alabama, Tuscaloosa, Alabama 35487, USA
| | - L Witthaus
- Department of Physics, TU Dortmund University, D-44221 Dortmund, Germany
| | - A Wolf
- III. Physikalisches Institut, RWTH Aachen University, D-52056 Aachen, Germany
| | - M Wolf
- Physik-department, Technische Universität München, D-85748 Garching, Germany
| | - G Wrede
- Erlangen Centre for Astroparticle Physics, Friedrich-Alexander-Universität Erlangen-Nürnberg, D-91058 Erlangen, Germany
| | - X W Xu
- Department of Physics, Southern University, Baton Rouge, Louisiana 70813, USA
| | - J P Yanez
- Department of Physics, University of Alberta, Edmonton, Alberta, Canada T6G 2E1
| | - E Yildizci
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - S Yoshida
- Department of Physics and The International Center for Hadron Astrophysics, Chiba University, Chiba 263-8522, Japan
| | - R Young
- Department of Physics and Astronomy, University of Kansas, Lawrence, Kansas 66045, USA
| | - F Yu
- Department of Physics and Laboratory for Particle Physics and Cosmology, Harvard University, Cambridge, Massachusetts 02138, USA
| | - S Yu
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - Z Zhang
- Department of Physics and Astronomy, Stony Brook University, Stony Brook, New York 11794-3800, USA
| | - P Zhelnin
- Department of Physics and Laboratory for Particle Physics and Cosmology, Harvard University, Cambridge, Massachusetts 02138, USA
| | - P Zilberman
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - M Zimmerman
- Department of Physics and Wisconsin IceCube Particle Astrophysics Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| |
Collapse
|
3
|
Zhang Y, Yu F, Long X, Fang W. Imaging features of temporomandibular joint synovial chondromatosis with associated osseous degenerative changes. Int J Oral Maxillofac Surg 2024; 53:311-318. [PMID: 37840000 DOI: 10.1016/j.ijom.2023.09.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2023] [Revised: 09/26/2023] [Accepted: 09/27/2023] [Indexed: 10/17/2023]
Abstract
Synovial chondromatosis (SC) of the temporomandibular joint (TMJ) is a rare benign disease associated with the formation of multiple cartilaginous nodules in the synovial tissue of the TMJ. This can result in pain, swelling, clicking, limited mouth opening, and osseous degenerative joint changes. A retrospective cross-sectional study was performed to summarize the clinical features, radiographic findings, and surgical and histopathological findings of TMJ SC patients who underwent open surgery over a 24-year period. A radiographic scoring system was used to evaluate osseous changes and correlate condyle and joint fossa degeneration. The study included 38 patients and focused on 38 joints. All 38 of these joints showed degenerative changes in the condyle, while 37 showed osseous degenerative changes in the articular fossa. The degree of condylar degenerative changes was related to the duration of the chief complaints (r = 0.342, P = 0.036) and the histopathological stage of the TMJ SC (r = 0.440, P = 0.006), while the degree of joint fossa degenerative changes was associated with the radiographic extent of the SC (r = 0.504, P = 0.001), type of calcification (r = 0.365, P = 0.024), and the histopathological stage (r = 0.458, P = 0.004).
Collapse
Affiliation(s)
- Y Zhang
- The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) and Key Laboratory of Oral Biomedicine Ministry of Education, School and Hospital of Stomatology, Wuhan University, Wuhan, Hubei, China; Department of Orthodontics, School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong University, Shandong Key Laboratory of Oral Tissue Regeneration, and Shandong Engineering Laboratory for Dental Materials and Oral Tissue Regeneration, Jinan, Shandong, China
| | - F Yu
- Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
| | - X Long
- The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) and Key Laboratory of Oral Biomedicine Ministry of Education, School and Hospital of Stomatology, Wuhan University, Wuhan, Hubei, China; Department of Oral and Maxillofacial Trauma and Temporomandibular Joint Surgery, School and Hospital of Stomatology, Wuhan University, Wuhan, Hubei, China
| | - W Fang
- The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) and Key Laboratory of Oral Biomedicine Ministry of Education, School and Hospital of Stomatology, Wuhan University, Wuhan, Hubei, China; Department of Oral and Maxillofacial Trauma and Temporomandibular Joint Surgery, School and Hospital of Stomatology, Wuhan University, Wuhan, Hubei, China.
| |
Collapse
|
4
|
Sanchez‐Martinez S, Nguyen K, Biswas S, Nicholson V, Romanyuk AV, Ramirez J, Kc S, Akter A, Childs C, Meese EK, Usher ET, Ginell GM, Yu F, Gollub E, Malferrari M, Francia F, Venturoli G, Martin EW, Caporaletti F, Giubertoni G, Woutersen S, Sukenik S, Woolfson DN, Holehouse AS, Boothby TC. Labile assembly of a tardigrade protein induces biostasis. Protein Sci 2024; 33:e4941. [PMID: 38501490 PMCID: PMC10949331 DOI: 10.1002/pro.4941] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2023] [Revised: 02/01/2024] [Accepted: 02/09/2024] [Indexed: 03/20/2024]
Abstract
Tardigrades are microscopic animals that survive desiccation by inducing biostasis. To survive drying tardigrades rely on intrinsically disordered CAHS proteins, which also function to prevent perturbations induced by drying in vitro and in heterologous systems. CAHS proteins have been shown to form gels both in vitro and in vivo, which has been speculated to be linked to their protective capacity. However, the sequence features and mechanisms underlying gel formation and the necessity of gelation for protection have not been demonstrated. Here we report a mechanism of fibrillization and gelation for CAHS D similar to that of intermediate filament assembly. We show that in vitro, gelation restricts molecular motion, immobilizing and protecting labile material from the harmful effects of drying. In vivo, we observe that CAHS D forms fibrillar networks during osmotic stress. Fibrillar networking of CAHS D improves survival of osmotically shocked cells. We observe two emergent properties associated with fibrillization; (i) prevention of cell volume change and (ii) reduction of metabolic activity during osmotic shock. We find that there is no significant correlation between maintenance of cell volume and survival, while there is a significant correlation between reduced metabolism and survival. Importantly, CAHS D's fibrillar network formation is reversible and metabolic rates return to control levels after CAHS fibers are resolved. This work provides insights into how tardigrades induce reversible biostasis through the self-assembly of labile CAHS gels.
Collapse
Affiliation(s)
| | - K. Nguyen
- Department of Molecular BiologyUniversity of WyomingLaramieWyomingUSA
| | - S. Biswas
- Department of Molecular BiologyUniversity of WyomingLaramieWyomingUSA
| | - V. Nicholson
- Department of Molecular BiologyUniversity of WyomingLaramieWyomingUSA
| | - A. V. Romanyuk
- School of ChemistryUniversity of BristolBristolUK
- Max Planck‐Bristol Centre for Minimal BiologyUniversity of BristolBristolUK
| | - J. Ramirez
- Department of Molecular BiologyUniversity of WyomingLaramieWyomingUSA
| | - S. Kc
- Department of Molecular BiologyUniversity of WyomingLaramieWyomingUSA
| | - A. Akter
- Department of Molecular BiologyUniversity of WyomingLaramieWyomingUSA
| | - C. Childs
- Department of Molecular BiologyUniversity of WyomingLaramieWyomingUSA
| | - E. K. Meese
- Department of Molecular BiologyUniversity of WyomingLaramieWyomingUSA
| | - E. T. Usher
- Department of Biochemistry and Molecular BiophysicsWashington University School of MedicineSt. LouisMissouriUSA
- Center for Biomolecular CondensatesWashington University in St. LouisSt. LouisMissouriUSA
| | - G. M. Ginell
- Department of Biochemistry and Molecular BiophysicsWashington University School of MedicineSt. LouisMissouriUSA
- Center for Biomolecular CondensatesWashington University in St. LouisSt. LouisMissouriUSA
| | - F. Yu
- Quantitative Systems Biology ProgramUniversity of California MercedMercedCaliforniaUSA
| | - E. Gollub
- Department of Chemistry and BiochemistryUniversity of California MercedMercedCaliforniaUSA
| | - M. Malferrari
- Dipartimento di Chimica “Giacomo Ciamician”Università di BolognaBolognaItaly
| | - F. Francia
- Laboratorio di Biochimica e Biofisica Molecolare, Dipartimento di Farmacia e Biotecnologie, FaBiTUniversità di BolognaBolognaItaly
| | - G. Venturoli
- Laboratorio di Biochimica e Biofisica Molecolare, Dipartimento di Farmacia e Biotecnologie, FaBiTUniversità di BolognaBolognaItaly
- Consorzio Nazionale Interuniversitario per le Scienze Fisiche della Materia (CNISM), c/o Dipartimento di Fisica e Astronomia (DIFA)Università di BolognaBolognaItaly
| | - E. W. Martin
- Department of Structural BiologySt. Jude Children's Research HospitalMemphisTennesseeUSA
| | - F. Caporaletti
- Van't Hoff Institute for Molecular SciencesUniversity of AmsterdamAmsterdamThe Netherlands
| | - G. Giubertoni
- Van't Hoff Institute for Molecular SciencesUniversity of AmsterdamAmsterdamThe Netherlands
| | - S. Woutersen
- Van't Hoff Institute for Molecular SciencesUniversity of AmsterdamAmsterdamThe Netherlands
| | - S. Sukenik
- Quantitative Systems Biology ProgramUniversity of California MercedMercedCaliforniaUSA
- Department of Chemistry and BiochemistryUniversity of California MercedMercedCaliforniaUSA
| | - D. N. Woolfson
- School of ChemistryUniversity of BristolBristolUK
- Max Planck‐Bristol Centre for Minimal BiologyUniversity of BristolBristolUK
- School of BiochemistryUniversity of Bristol, Biomedical Sciences BuildingBristolUK
| | - A. S. Holehouse
- Department of Biochemistry and Molecular BiophysicsWashington University School of MedicineSt. LouisMissouriUSA
- Center for Biomolecular CondensatesWashington University in St. LouisSt. LouisMissouriUSA
| | - T. C. Boothby
- Department of Molecular BiologyUniversity of WyomingLaramieWyomingUSA
| |
Collapse
|
5
|
Yu F, Wang ZX, Yu J, Hu FJ, Zhang RG, Yuan Y, Yang W. Study on the construction of nomogram prediction model for prognostic assessment of heart failure patients based on serological markers and echocardiography. Eur Rev Med Pharmacol Sci 2024; 28:2837-2847. [PMID: 38639523 DOI: 10.26355/eurrev_202404_35913] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/20/2024]
Abstract
OBJECTIVE We aimed to construct a nomogram prediction model for prognostic assessment of patients with heart failure (HF) based on serological markers and echocardiography. PATIENTS AND METHODS A total of 200 HF patients admitted to the Second Affiliated Hospital of Nanchang University from January 2018 to January 2020 were selected as the research objects. According to the New York Heart Association (NYHA) cardiac function classification, they were divided into 3 groups, including 65 cases of grade II, 97 cases of grade III, and 38 cases of grade IV. Three groups of echocardiographic parameters were compared [including left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), left ventricular end-systolic volume (LVESV)], differences in serum markers brain natriuretic peptide (BNP), soluble growth-stimulating expression gene 2 (sST2) and the Modified Early Warning Score (MEWS). The patients were divided into two groups according to their clinical outcomes during the follow-up period, including 52 cases in the death group and 148 cases in the survival group. The clinical data of the two groups were compared, and multi-factor logistic regression analysis was performed to screen out the independent risk factors affecting the patient's death. A nomogram model of the patient's mortality risk was constructed based on the independent risk factors. Receiver operating characteristic (ROC) curves and calibration curves were used to evaluate the discrimination and accuracy of the nomogram model. RESULTS As the cardiac function class of elderly chronic heart failure (CHF) patients increases, LVEDD, LVESD, sST2, and MEWS increase and LVEF decreases (p<0.05). Multifactor analysis results showed that LVEF, LVEDD, sST2, and MEWS were independent factors affecting the clinical outcome of patients. The AUCs predicted using LVEF, LVEDD, sST2, and MEWS alone were 0.738, 0.775, 0.717, 0.831, and 0.768, respectively. There is a certain degree of discrimination, and the model has extremely high accuracy. CONCLUSIONS MEWS, LVEDD, and sST2 increase as the NYHA cardiac function grade of HF patients increases and LVEF decreases, which can reflect the severity of the disease to a certain extent. Additionally, the nomogram model established based on this has a high predictive value for the long-term prognosis of patients and can formulate effective intervention measures for quantitative values.
Collapse
Affiliation(s)
- F Yu
- Department of Cardiac and Vascular Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang City, Jiangxi Province, China.
| | | | | | | | | | | | | |
Collapse
|
6
|
Yu J, Da J, Yu F, Yuan J, Zha Y. HMGN1 down-regulation in the diabetic kidney attenuates tubular cells injury and protects against renal inflammation via suppressing MCP-1 and KIM-1 expression through TLR4. J Endocrinol Invest 2024; 47:1015-1027. [PMID: 38409569 DOI: 10.1007/s40618-023-02292-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/17/2023] [Accepted: 12/20/2023] [Indexed: 02/28/2024]
Abstract
BACKGROUND Renal tubular injury, accompanied by damaging inflammation, has been identified to drive diabetic kidney disease (DKD) toward end-stage renal disease. However, it is unclear how damage-associated molecular patterns (DAMPs) activate innate immunity to mediate tubular epithelial cell (TEC) injury, which in turn causes with subsequent sterile inflammation in diabetic kidneys. High mobility group nucleosome-binding protein 1 (HMGN1) is a novel DAMP that contributes to generating the innate immune response. In this study, we focused on determining whether HMGN1 is involved in DKD progression. METHODS Streptozotocin (STZ)-induced diabetic mice model was established. Then we downrergulated HMGN1 expression in kidney with or without HMGN1 administration. The renal dysfunction and morphological lesions in the kidneys were evaluated. The expressions of KIM-1, MCP-1, F4/80, CD68, and HMGN1/TLR4 signaling were examined in the renal tissue. In vitro, HK2 cells were exposed in the high glucose with or without HMGN1, and further pre-incubated with TAK242 was applied to elucidate the underlying mechanism. RESULTS We demonstrated that HMGN1 was upregulated in the tubular epithelial cells of streptozotocin (STZ)-induced type 1 and type 2 diabetic mouse kidneys compared to controls, while being positively correlated with increased TLR4, KIM-1, and MCP-1. Down-regulation of renal HMGN1 attenuated diabetic kidney injury, decreased the TLR4, KIM-1, and MCP-1 expression levels, and reduced interstitial infiltrating macrophages. However, these phenotypes were reversed after administration of HMGN1. In HK-2 cells, HMGN1 promoted the expression of KIM-1 and MCP-1 via regulating MyD88/NF-κB pathway; inhibition of TLR4 effectively diminished the in vitro response to HMGN1. CONCLUSIONS Our study provides novel insight into HMGN1 signaling mechanisms that contribute to tubular sterile injury and low-grade inflammation in DKD. The study findings may help to develop new HMGN1-targeted approaches as therapy for immune-mediated kidney damage rather than as an anti-infection treatments.
Collapse
Affiliation(s)
- J Yu
- School of Medicine, Guizhou University, Guiyang, Guizhou, China
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China
| | - J Da
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China
| | - F Yu
- School of Medicine, Guizhou University, Guiyang, Guizhou, China
- NHC Key Laboratory of Pulmonary Immunological Disease, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China
| | - J Yuan
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China
| | - Y Zha
- Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China.
- NHC Key Laboratory of Pulmonary Immunological Disease, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China.
| |
Collapse
|
7
|
Hu X, Hu Q, He Y, Yi X, Wu Z, Hu H, Ouyang Y, Yu F, Peng M. Efficacy and safety of microwave ablation and its synergistic potential in the treatment of early-stage non-small cell lung cancer. Clin Imaging 2024; 107:110070. [PMID: 38211397 DOI: 10.1016/j.clinimag.2023.110070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2023] [Revised: 12/21/2023] [Accepted: 12/30/2023] [Indexed: 01/13/2024]
Abstract
Lung cancer remains the primary cause of cancer-related mortality globally. In the case of early-stage non-small cell lung cancer (NSCLC), surgical resection, such as lobectomy and sub-lobectomy, continues to be the established standard treatment. However, for patients with insufficient cardiopulmonary function and multiple comorbidities who are unable to undergo surgical resection, nonoperative local therapies, including radiotherapy and thermal ablation, are preferred. In recent years, microwave ablation (MWA) has gained popularity for treating early-stage NSCLC due to its high heating efficiency, good tissue conductance, and heat conduction capabilities. This review provides a comprehensive summary of the current efficacy and safety data regarding MWA for early-stage NSCLC and discusses the potential benefits of combining MWA with other therapies.
Collapse
Affiliation(s)
- Xinhang Hu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China; Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Qikang Hu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China; Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Yu He
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China; Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Xuyang Yi
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China; Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Zeyu Wu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China; Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Huali Hu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China; Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Yifan Ouyang
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China; Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Fenglei Yu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China; Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China.
| | - Muyun Peng
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China; Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China.
| |
Collapse
|
8
|
Zhang X, Cai Z, Liu B, Liao J, Yu F, Tan Z, Wang B, Yang M, Zhang B. Finite element analysis and clinical study of chest wall reconstruction using carbon fiber artificial rib. Sci Rep 2024; 14:97. [PMID: 38167575 PMCID: PMC10762004 DOI: 10.1038/s41598-023-50716-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2023] [Accepted: 12/23/2023] [Indexed: 01/05/2024] Open
Abstract
Carbon fiber composites are emerging as a promising new biomaterial for chest wall reconstruction implants due to their mechanical properties and biocompatibility. This work evaluates the biomechanics of carbon fiber artificial ribs using finite element analysis and clinical implementation. Static simulations of normal breathing process show the maximum stress on the implant is only 2.83 MPa, far below the material ultimate strength of 60 MPa, indicating the excellent fit for maintaining respiratory function. Dynamic collision simulations demonstrate the artificial rib model could withstand a 4 kg rigid object impact at 2 m/s without fracture. Reconstructing the artificial rib with a human rib in the finite element analysis model increases the overall stress tolerance. The impact force required for fracture increases 48% compared to the artificial rib alone, suggesting improved strength from rib integration. Clinically, 10 of 13 patients receiving the artificial rib implants show no significant loss of pulmonary function based on spirometry tests. Based on our findings, the combined simulations and clinical results validate the strong mechanical performance and biocompatibility of the carbon fiber artificial ribs for chest wall reconstruction under static and dynamic loading while maintaining normal respiratory function.
Collapse
Affiliation(s)
- Xiang Zhang
- Hunan Tankang Biotech Co., LTD., Changsha, 410083, Hunan Province, People's Republic of China
| | - Zhixia Cai
- Hunan Tankang Biotech Co., LTD., Changsha, 410083, Hunan Province, People's Republic of China
| | - Bo Liu
- Hunan Tankang Biotech Co., LTD., Changsha, 410083, Hunan Province, People's Republic of China
| | - Jiqiao Liao
- Hunan Tankang Biotech Co., LTD., Changsha, 410083, Hunan Province, People's Republic of China
| | - Fenglei Yu
- Department of Thoracic Surgery, the Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan Province, People's Republic of China
| | - Zhoujian Tan
- Hunan Tankang Biotech Co., LTD., Changsha, 410083, Hunan Province, People's Republic of China.
| | - Bin Wang
- Department of Thoracic Surgery, the Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan Province, People's Republic of China.
| | - Mei Yang
- College of Mechanical and Electrical Engineering, Central South University, Changsha, 410083, Hunan Province, People's Republic of China.
| | - Bowen Zhang
- College of Mechanical and Electrical Engineering, Central South University, Changsha, 410083, Hunan Province, People's Republic of China
| |
Collapse
|
9
|
Yu F, Fu J, Tan M, Xu R, Tian Y, Jia L, Zhang D, Wang Q, Gao Z. Norovirus outbreaks in hospitals in China: a systematic review. J Hosp Infect 2023; 142:32-38. [PMID: 37805116 DOI: 10.1016/j.jhin.2023.09.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2023] [Revised: 09/20/2023] [Accepted: 09/21/2023] [Indexed: 10/09/2023]
Abstract
BACKGROUND Norovirus outbreaks in hospitals can potentially impair patient care and result in significant financial expenses. There is currently limited information on hospital norovirus outbreaks in the Chinese mainland. AIM To systematically review the published literature to describe the characteristics of norovirus outbreaks in Chinese mainland hospitals to facilitate prompt identification and control of outbreaks. METHODS A systematic review was performed according to the Preferred Reporting Items for Systematic Review and Meta-Analysis standards. Databases including PubMed, Web of Science, and Chinese Journals Online databases (China National Knowledge Infrastructure (CNKI), Chinese Wan Fang digital database (WANFANG) were searched from inception to July 18th, 2022. FINDINGS A total of 41 norovirus Chinese hospital outbreaks occurring before July 18th, 2022 were reported in 32 articles. Most reported outbreaks were from Shanghai and Beijing, and occurred in December and January. Cases were mainly adults. The male:female ratio was 1.22:1. The majority of cases in norovirus outbreaks were hospitalized patients (56.82%); medical staff were affected in 15 outbreaks. Norovirus outbreaks occurred in both private and public hospitals, and in secondary and tertiary care centres, and occurred mainly in internal medicine and geriatric departments. Person-to-person transmission was the primary transmission mode and GII was more prevalent. CONCLUSION Norovirus outbreaks in hospitals can affect both patients and healthcare workers, sometimes causing serious financial losses. In order to have a more complete understanding of the disease burden caused by norovirus outbreaks, surveillance needs to be established in hospitals.
Collapse
Affiliation(s)
- F Yu
- The University of Hong Kong, School of Public Health, Hong Kong, China
| | - J Fu
- China Medical University, School of Public Health, Shenyang, China
| | - M Tan
- China Medical University, School of Public Health, Shenyang, China
| | - R Xu
- China Medical University, School of Public Health, Shenyang, China
| | - Y Tian
- China Medical University, School of Public Health, Shenyang, China
| | - L Jia
- Beijing Center for Disease Prevention and Control, Beijing, China
| | - D Zhang
- Beijing Center for Disease Prevention and Control, Beijing, China
| | - Q Wang
- Beijing Center for Disease Prevention and Control, Beijing, China
| | - Z Gao
- Beijing Center for Disease Prevention and Control, Beijing, China.
| |
Collapse
|
10
|
Song X, Wang C, He H, Peng M, Hu Q, Wang B, Tang L, Yu F. Association of phthalate exposure with pulmonary function in adults: NHANES 2007-2012. Environ Res 2023; 237:116902. [PMID: 37625539 DOI: 10.1016/j.envres.2023.116902] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/30/2023] [Revised: 07/03/2023] [Accepted: 08/15/2023] [Indexed: 08/27/2023]
Abstract
BACKGROUND Epidemiological evidence for the adverse effect of phthalate exposure on respiratory health is on the rise, but cross-sectional studies regarding its effects on lung function are limited and contradictory, especially in adults. OBJECTIVE To assess the associations between individual and a mixture of urinary phthalate metabolites and adult pulmonary function in the United States, and to identify which ones were primarily responsible for impaired respiratory function. METHODS We obtained a cross-sectional data on 3788 adults aged 20 years and older from the National Health and Nutrition Examination Survey (2007-2012). Respiratory function was evaluated using spirometry, and phthalate exposure was assessed by measuring the levels of ten urinary phthalate metabolites. The effects of individual and mixed phthalate metabolites exposure on lung function were assessed using multivariate linear regression models and the repeated holdout weighted quantile sum (WQS) regression models, respectively, after adjusting for potential confounders including age, gender, family poverty income ratio, body mass index, and serum cotinine. RESULTS When modeled as continuous variables or quantiles, urinary phthalate metabolites, including mono-ethyl phthalate (MEP), mono-n-butyl phthalate, mono-iso-butyl phthalate, mono-benzyl phthalate, mono-(2-ethyl-5-oxohexyl) phthalate, mono-(2-ethyl-5-hydroxyhexyl) phthalate, mono-(2-ethyl-5-carboxypentyl) phthalate (MECPP), mono-(3-carboxypropyl) phthalate, and mono-carboxyoctyl phthalate, were identified to be negatively associated with forced vital capacity in percent predicted values (ppFVC) and forced expiratory volume in the first second in percent predicted values (ppFEV1). In addition, per each decile increase in the WQS index, ppFVC (β = -2.87, 95% CI: -3.56, -2.08) and ppFEV1 (β = -2.53, 95% CI: -3.47, -1.54) declined significantly, primarily due to the contribution of MEP and MECPP. Furthermore, there were no significant interactions between co-exposure to urinary phthalate metabolites and each covariate. CONCLUSION Our findings reveal that urinary phthalate metabolites are significantly associated with adult respiratory decrements, with diethyl and di-(2-ethylhexyl) phthalate contributing the most to the impaired lung function.
Collapse
Affiliation(s)
- Xinli Song
- School of Public Health, Institute of Child and Adolescent Health, Peking University, Beijing, China; National Health Commission Key Laboratory of Reproductive Health, Beijing, China
| | - Cheng Wang
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Hao He
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Muyun Peng
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Qikang Hu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Bin Wang
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Lei Tang
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Fenglei Yu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.
| |
Collapse
|
11
|
Huang JL, Wang X, Yu F, Li MY, Tang YT. [Vaginal microbiota abnormalities in women with unexplained infertility and its treatment]. Zhonghua Yu Fang Yi Xue Za Zhi 2023; 57:1813-1819. [PMID: 38008571 DOI: 10.3760/cma.j.cn112150-20230322-00217] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 11/28/2023]
Abstract
The vaginal microbiota is a complex and dynamic environment that plays an important role in the healthy reproduction of women. The mechanism of unexplained infertility is not yet clear, and the imbalance and low stability of vaginal microbiota may be related to unexplained infertility. Taking probiotic composite preparations to restore normal vaginal microbiota may be a safe and natural method for treating unexplained infertility. This article reviews the probiotic composite preparations used in the treatment of unexplained infertility both domestically and internationally, including the isolation site of the bacterial species, the use method of the composite preparation, the course of treatment, and the final therapeutic effect, aiming to provide a basis for the clinical application of probiotic composite preparations in the treatment of unexplained infertility.
Collapse
Affiliation(s)
- J L Huang
- Department of Laboratory Medicine, West China Second University Hospital, Sichuan University/Key Laboratory of Birth Defects and Related Maternal and Child Diseases, Ministry of Education, Chengdu 610041, China
| | - X Wang
- Department of Laboratory Medicine, West China Second University Hospital, Sichuan University/Key Laboratory of Birth Defects and Related Maternal and Child Diseases, Ministry of Education, Chengdu 610041, China
| | - F Yu
- Department of Laboratory Medicine, West China Second University Hospital, Sichuan University/Key Laboratory of Birth Defects and Related Maternal and Child Diseases, Ministry of Education, Chengdu 610041, China
| | - M Y Li
- Department of Laboratory Medicine, West China Second University Hospital, Sichuan University/Key Laboratory of Birth Defects and Related Maternal and Child Diseases, Ministry of Education, Chengdu 610041, China
| | - Y T Tang
- Department of Laboratory Medicine, West China Second University Hospital, Sichuan University/Key Laboratory of Birth Defects and Related Maternal and Child Diseases, Ministry of Education, Chengdu 610041, China
| |
Collapse
|
12
|
Hu Q, Frank ML, Gao Y, Ji L, Peng M, Chen C, Wang B, Hu Y, Wu Z, Li J, Shu L, He Q, Zhang Y, Xia X, Zhang J, Yi X, Reuben A, Yu F. Spatial heterogeneity of T cell repertoire across NSCLC tumors, tumor edges, adjacent and distant lung tissues. Oncoimmunology 2023; 12:2233399. [PMID: 37876834 PMCID: PMC10591778 DOI: 10.1080/2162402x.2023.2233399] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2022] [Accepted: 07/02/2023] [Indexed: 10/26/2023] Open
Abstract
Background A better understanding of T cells in lung cancer and their distribution across tumor-adjacent lungs and peripheral blood is needed to improve efficacy and minimize toxicity from immunotherapy to lung cancer patients. Methods Here, we performed CDR3β TCR sequencing of 136 samples from 20 patients with early-stage NSCLC including peripheral blood mononuclear cells, tumors, tumor edges (<1 cm from tumor), as well as adjacent lungs 1 cm, 2 cm, 5 cm, and 10 cm away from the tumor to gain insight into the spatial heterogeneity of T cells across the lungs in patients with NSCLC. PD-L1, CD4, and CD8 expression was assessed using immunohistochemical staining, and genomic features were derived by targeted sequencing of 1,021 cancer-related genes. Multiplex immunohistochemistry against PD-1, CTLA4, LAG3, and TIM3 was performed on four patients to assess T cell exhaustion. Results Our study reveals a decreasing gradient in TIL Tumor Infiltrating Lymphocytes homology with tumor edge, adjacent lungs, and peripheral blood but no discernible distance-associated patterns of T cell trafficking within the adjacent lung itself. Furthermore, we show a decrease in pathogen-specific TCRs in regions with high T cell clonality and PD-L1 expression. Conclusions Exclusion in T exhaustion cells at play across the lungs of patients with NSCLC may potentially be the mechanism for lung cancer occurrence.
Collapse
Affiliation(s)
- Qikang Hu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, P. R. China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
- Early-Stage Lung Cancer Center, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Meredith L. Frank
- Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA
| | - Yang Gao
- Department of Thoracic Surgery, Xiangya Hospital, Central South University, Changsha, P. R. China
- Xiangya Lung Cancer Center, Xiangya Hospital, Central South University, Changsha, China
- Hunan Engineering Research Center for Pulmonary Nodules Precise Diagnosis & Treatment, Changsha, China
- National Clinical Research Center for Geriatric Disorders, Changsha, China
| | - Liyan Ji
- Geneplus-Beijing Institute, Beijing, China
| | - Muyun Peng
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, P. R. China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
- Early-Stage Lung Cancer Center, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Chen Chen
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, P. R. China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
- Early-Stage Lung Cancer Center, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Bin Wang
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, P. R. China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
- Early-Stage Lung Cancer Center, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Yan Hu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, P. R. China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
- Early-Stage Lung Cancer Center, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Zeyu Wu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, P. R. China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
- Early-Stage Lung Cancer Center, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Jina Li
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, P. R. China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
- Early-Stage Lung Cancer Center, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Lu Shu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, P. R. China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
- Early-Stage Lung Cancer Center, The Second Xiangya Hospital of Central South University, Changsha, China
| | | | | | | | - Jianjun Zhang
- Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA
- Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, USA
- Lung Cancer Genomics Program, University of Texas MD Anderson Cancer Center, Houston, USA
- Lung Cancer Interception Program, University of Texas MD Anderson Cancer Center, Houston, USA
| | - Xin Yi
- Geneplus-Beijing Institute, Beijing, China
| | - Alexandre Reuben
- Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA
| | - Fenglei Yu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, P. R. China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
- Early-Stage Lung Cancer Center, The Second Xiangya Hospital of Central South University, Changsha, China
| |
Collapse
|
13
|
Peng M, Hu Q, Wu Z, Wang B, Wang C, Yu F. Mutation of TP53 Confers Ferroptosis Resistance in Lung Cancer Through the FOXM1/MEF2C Axis. Am J Pathol 2023; 193:1587-1602. [PMID: 37236507 DOI: 10.1016/j.ajpath.2023.05.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/12/2023] [Revised: 04/17/2023] [Accepted: 05/02/2023] [Indexed: 05/28/2023]
Abstract
Ferroptosis is a highly regulated tumor suppressor process. Loss or mutation of TP53 can cause changes in sensitivity to ferroptosis. Mutations in TP53 may be associated with the malignant or indolent progression of ground glass nodules in early lung cancer, but whether ferroptosis may also be involved in determining this biological process has not yet been determined. Using in vivo and in vitro gain- and loss-of-function approaches, this study used clinical tissue for mutation analysis and pathological research to show that wild-type TP53 inhibited the expression of forkhead box M1 (FOXM1) by binding to peroxisome proliferator-activated receptor-γ coactivator 1α, maintaining the mitochondrial function and thus affecting the sensitivity to ferroptosis. This function was absent in mutant cells, resulting in overexpression of FOXM1 and ferroptosis resistance. Mechanistically, FOXM1 activated the transcription level of myocyte-specific enhancer factor 2C in the mitogen-activated protein kinase signaling pathway, leading to stress protection when exposed to ferroptosis inducers. This study provides new insights into the mechanism of association between TP53 mutation and ferroptosis tolerance, which can aid a deeper understanding of the role of TP53 in the malignant progression of lung cancer.
Collapse
Affiliation(s)
- Muyun Peng
- Department of Thoracic Surgery, The Second Xiangya Hospital, Central South University, Changsha, People's Republic of China
| | - Qikang Hu
- Department of Thoracic Surgery, The Second Xiangya Hospital, Central South University, Changsha, People's Republic of China
| | - Zeyu Wu
- Department of Thoracic Surgery, The Second Xiangya Hospital, Central South University, Changsha, People's Republic of China
| | - Bin Wang
- Department of Thoracic Surgery, The Second Xiangya Hospital, Central South University, Changsha, People's Republic of China
| | - Cheng Wang
- Department of Thoracic Surgery, The Second Xiangya Hospital, Central South University, Changsha, People's Republic of China
| | - Fenglei Yu
- Department of Thoracic Surgery, The Second Xiangya Hospital, Central South University, Changsha, People's Republic of China.
| |
Collapse
|
14
|
Zhao L, Yang Y, Liu P, Yu F, Hu L, Kang M, Lin H, Ding X. Introducing an Experimental Approach to Predict Spot Scanning Time Parameters for a Superconducting Cyclotron Proton Therapy Machine. Int J Radiat Oncol Biol Phys 2023; 117:e748. [PMID: 37786166 DOI: 10.1016/j.ijrobp.2023.06.2290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Proton pencil beam scanning (PBS) delivery sequence varies a lot among institutions due to the differences in vendors, machine types, and beamline configurations, which impacts PBS interplay effects and treatment delivery time estimation. This study aims to develop an independent experimental approach to predict the spot scanning time parameters for a clinical superconducting cyclotron proton therapy machine. MATERIALS/METHODS This independent experimental approach employed an open-air parallel-plate detector with a temporal resolution of 0.05ms. A series of spot, energy, and dose rate patterns were designed and delivered, including (1) Spot switching time (SSWT) under different spot spacing for IEC-X, IEC-Y directions and diagonal direction (traveling in both X and Y direction) for three energy layers (110, 170 and 230 MeV); The Wilcoxon test is used to validate the prediction of SSWT along the diagonal direction. (2) Energy layer switching time (ELST) with different descending energy gaps for a fixed initial energy and different initial energies for a fixed descending energy gap. (3) Dose rate (MU/min) are measured for different minimum-MU-per-energy-layer (MMPEL), which are compared with the previous publication. RESULTS A SSWT jump at 10mm (can be customized) spot spacing is observed because of triggering the machine's "raster mode" threshold. Discontinuous two variable piecewise linear functions were used to fit the SSWT in X/Y for spot spacing and energy. SSWT in X/Y is increasing as spot spacing and energy increase. SSWT in the diagonal direction is determined by the time either in the x-direction or y-direction, whichever takes longer (see Table 1 for one example of validations). ELST is linear depending on descending energy gap. The dose rate dependence on MMPEL is confirmed with previous publications of a similar type of machine. CONCLUSION The study provided the first independent quantitative experimental modeling of the beam delivery time parameters without any information from vendors. Such machine-specific delivery sequence models could pave the foundation of precise interplay effect evaluation for clinical decision-making.
Collapse
Affiliation(s)
- L Zhao
- Department of Radiation Oncology, Corewell Health William Beaumont University Hospital, Royal Oak, MI
| | - Y Yang
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY
| | - P Liu
- Department of Radiation Oncology, Corewell Health William Beaumont University Hospital, Royal Oak, MI
| | - F Yu
- New York Proton Center, New York, NY
| | - L Hu
- New York Proton Center, New York, NY
| | - M Kang
- New York Proton Center, New York, NY
| | - H Lin
- New York Proton Center, New York, NY
| | - X Ding
- Department of Radiation Oncology, Corewell Health William Beaumont University Hospital, Royal Oak, MI
| |
Collapse
|
15
|
Lin H, Yu F, Gorovets D, Kabarriti R, Alektiar KM, Ohri N, Hasan S, Tsai P, Shim A, Kang M, Barker CA, Wolden SL, Hajj C, Mehta KJ, Lee NY, Chhabra AM, Shepherd AF, Choi IJ, Yamada Y, Simone CB. Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy (SBRT): A Robust Single Institution Experience. Int J Radiat Oncol Biol Phys 2023; 117:e686-e687. [PMID: 37786018 DOI: 10.1016/j.ijrobp.2023.06.2155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) To describe the feasibility of treating a complex and diverse group of patients using pencil beam scanning (PBS) proton stereotactic body radiation therapy (SBRT: 5 or fewer fractions, with a fraction size of at least 5 Gy). MATERIALS/METHODS Our center treats on average 105-120 PBS proton treatments daily, of which 9.5% of treatment courses are proton SBRT. Statistics of disease sites, treatment planning parameters (target volume, prescriptions, number of fields, SFO vs. MFO), and treatment efficiencies (scheduled time slots, actual treatment time) are presented for 305 consecutive SBRT patients receiving 1507 fractions in the past three years. Thermoplastic masks or Vacuum-lock bags are used to immobilize SBRT patients and index the patients' treatment position. Imaging guidance of orthogonal kV images and volumetric cone-beam CT is routinely used for patient setup. RESULTS SBRT patients are grouped based on the target locations: pelvis (31%), liver (17%), thoracic (13%), spine (8%), abdominal (8%), brain (7%), non-spine bone (7%), ocular (6%), and head and neck (2%). Only 112 patients (37%) were receiving their 1st RT course, whereas 113 (37%) had one prior in-field RT course, and 80 (26%) had multiple prior in-field RT courses. The median [IQR] target volume was 65.4 [29.3, 168] cc (range: 0.3-2475 cc). 72% of cases were planned with SFO and 28% with MFO. On average, 3.76 fields (range: 2 to 12) were planned for each treatment. 44% of the treatments were planned with three or fewer fields, and 10% received more than five fields, most of which involved repainting for moving targets. Over 97% of treatments were delivered in 5 fractions, with ∼3% delivered in 3 fractions. The median [IQR] prescription per treatment was 8 [7, 10] Gy (range: 5-18 Gy per treatment). 85% (84%) of the SBRT treatments were scheduled (delivered) in a 45-minute or shorter slot, and 6% (7%) of treatments were scheduled (delivered) in over a one-hour slot, most commonly for multiple isocenter treatments. 93% of treatments were delivered within 15 minutes of the planned treatment time or shorter. Deep-inspiration breath-hold (DIBH) was applied to 45% of liver SBRT cases, with the remaining 55% planned on 4D CT with (14%) or without (86%) abdominal compression. DIBH was applied in 13% of lung SBRT cases. The application of other motion mitigation approaches, such as volumetric repainting, was determined by the target motion amplitude and whether the patient could tolerate DIBH. CONCLUSION In the most diverse and largest proton SBRT experience delivered in the world over the past 3 years, over 300 patients were treated, demonstrating the feasibility and efficiency of delivering proton SBRT in a very busy center. The planning and treatment parameter statistics reported serve as a helpful reference for the proton community.
Collapse
Affiliation(s)
- H Lin
- New York Proton Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY
| | - F Yu
- New York Proton Center, New York, NY
| | - D Gorovets
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - R Kabarriti
- Department of Radiation Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY
| | - K M Alektiar
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - N Ohri
- Department of Radiation Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY
| | - S Hasan
- New York Proton Center, New York, NY; Department of Radiation Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY
| | - P Tsai
- New York Proton Center, New York, NY
| | - A Shim
- New York Proton Center, New York, NY
| | - M Kang
- New York Proton Center, New York, NY
| | - C A Barker
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - S L Wolden
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - C Hajj
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - K J Mehta
- Department of Radiation Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY
| | - N Y Lee
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - A M Chhabra
- New York Proton Center, New York, NY; Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
| | - A F Shepherd
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - I J Choi
- New York Proton Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY
| | - Y Yamada
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - C B Simone
- New York Proton Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY
| |
Collapse
|
16
|
Abeloos CH, Gorovets D, Lewis A, Ji W, Lozano A, Tung CC, Yu F, Hanlon A, Lin H, Kha A, Yamada Y, Kabarriti R, Lazarev S, Hasan S, Chhabra AM, Simone CB, Choi IJ. Prospective Evaluation of Patient-Reported Outcomes of Invisible Ink Tattoos for the Delivery of External Beam Radiation Therapy: The PREFER Trial. Int J Radiat Oncol Biol Phys 2023; 117:e234. [PMID: 37784934 DOI: 10.1016/j.ijrobp.2023.06.1152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Invisible ink tattoos allow for setup accuracy while avoiding the cosmetic permanence of visible ink tattoos. The goal of this trial was to evaluate patient-reported preference for the use of invisible ink tattoos in a radiation oncology clinic. MATERIALS/METHODS In an IRB-approved, prospective, feasibility trial, patients at a single institution receiving pencil beam scanning proton therapy to the thorax, abdomen, or pelvis underwent invisible ink tattoo-based treatment setup. Patient preference surveys comparing visible and invisible ink tattoos were completed prior to simulation (17 questions), immediately following simulation (5 questions), and at the end of treatment (18 questions), with preference scored on a 5-point Likert scale from strongly disagree to strongly agree, and cosmesis scored on a 4-point Likert scale of excellent-good-fair-poor. Differences in distributions were examined using Wilcoxon rank-sum tests, Fisher's exact tests, or chi-square tests, where statistical significance was considered at p<0.05. RESULTS Of 107 patients screened, 102 were enrolled and 94 completed all surveys. Mean age was 55.0 years, and 58.5% were female. Most patients were white (79.1%) and non-Hispanic (92.6%). Patients most commonly had breast (34.0%), prostate (16.0%), and lung (9.6%) cancer. An average of 5 (range 3-8) invisible ink tattoos were placed per patient. Overall, 75.5% of patients reported that they would prefer to receive invisible tattoos vs. visible tattoos, and 88.3% rated the overall cosmetic outcome of invisible ink tattoo marks as excellent or good. Compared to males, females were more willing to travel farther from their home in order to avoid receiving visible tattoos (45.4% vs. 23.1%, p = 0.035) and would pay additional money to avoid receiving visible tattoos (34.5% vs. 5.1%, p = 0.002). Patients who had previously received any tattoo (cosmetic or visible RT tattoos) were more satisfied with the appearance of their invisible ink tattoos compared to those who had never previously received tattoos (82.9% vs. 61.5%, p = 0.022). Patients receiving definitive intent RT were more satisfied with the appearance of the tattoos compared to those receiving palliative intent RT (67.1% vs. 38.9%, p = 0.011). Patients with at least a college education were less satisfied with the appearance of tattoos compared to those without a college education (67.0% vs. 95.0% p = 0.018). CONCLUSION These findings demonstrate stronger avoidance of visible tattoos and patient preference for invisible tattoos. The standard incorporation of invisible ink tattoos for patient setup should be strongly considered.
Collapse
Affiliation(s)
| | - D Gorovets
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - A Lewis
- Rutgers Robert Wood Johnson, Newark, NJ
| | - W Ji
- Virginia Tech, Roanoke, VA
| | | | - C C Tung
- New York Proton Center, New York, NY
| | - F Yu
- New York Proton Center, New York, NY
| | | | - H Lin
- New York Proton Center, New York, NY
| | - A Kha
- New York Proton Center, New York, NY
| | - Y Yamada
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - R Kabarriti
- Department of Radiation Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY
| | - S Lazarev
- Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
| | - S Hasan
- New York Proton Center, New York, NY
| | | | - C B Simone
- Memorial Sloan Kettering Cancer Center, New York, NY; New York Proton Center, New York, NY
| | - I J Choi
- Memorial Sloan Kettering Cancer Center, New York, NY; New York Proton Center, New York, NY
| |
Collapse
|
17
|
Marshall DC, Shim A, Chen CC, Lin H, Yu F, Argiriadi P, Choi IJ, Chhabra AM, Simone CB. A Dosimetric Assessment of Sexual Organ Sparing Proton Radiotherapy in Female Pelvic Cancer Patients. Int J Radiat Oncol Biol Phys 2023; 117:e695. [PMID: 37786040 DOI: 10.1016/j.ijrobp.2023.06.2174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Optimizing treatment techniques for female patients undergoing curative treatment for pelvic cancers requires incorporating the goals of maximizing cure while maintaining quality of life. Optimizing treatment to maintain sexual quality of life has received little attention in female patients despite the presence of and toxicity risks to functional anatomic organs and their associated neurovasculature, including the bulboclitoris, vagina, and ovaries. Recent dosimetric data without employing sexual organ sparing suggest that mean VMAT dose to the bulboclitoris in low rectal cancer is around 3300 cGy, and in anal cancer, mean dose is around 2000 cGy to the external genitalia and 4500-5000 cGy to the bulboclitoris, all of which would be expected to result in clinically significant toxicity. Therefore, investigation of the avoidance of these important organs is needed and we hypothesize that proton techniques may achieve greater sparing than photon techniques. MATERIALS/METHODS In this study, we dosimetrically compare proton- vs. photon-based techniques in sparing functional sexual organs. The cohort consisted of four consecutive female pelvic cancer cases that had received 5000 cGy or greater. All cases were re-planned with VMAT and protons while optimizing dose to functional sexual organs and maintaining target coverage. Sexual organ structures assessed include the genitalia, vagina, ovaries, bulboclitoris and internal pudendal arteries. Given the small number of patients included in this demonstration study, statistical tests were not performed. RESULTS MRI was required to appropriately delineate soft tissue. In all cases, dosimetric sparing of sexual organs was improved with proton therapy without compromising target coverage. Mean doses were marginally decreased for structures within the PTV, while structures such as the bulboclitoris were spared substantially. Mean dose to the external genitalia was low with sparing using both VMAT (Median [IQR] (cGy): 852 [811, 1090]) and Proton techniques (Median [IQR] (cGy): 39.4 [11.9, 78.5]). Similarly, mean dose with sparing to the external genitalia was lower than would be expected without sparing, using both VMAT and Proton techniques (Median (IQR) Dmean (cGy) VMAT 3100 [2890, 3580] vs. Proton 1530 [1100, 2090]), with protons demonstrating greater sparing. In one case of a sacral chordoma, ovaries were substantially spared to below ablative thresholds (Dmean (cGy) VMAT 3598.8 and 3548.0 vs Proton 34.1 and 103.3). CONCLUSION Magnetic resonance imaging at simulation combined with proton radiotherapy for female sexual organ sparing may provide a technically feasible route to more equitable sexual outcomes for female patients. These results will guide future studies to optimize proton treatment techniques for female sexual organ sparing for future trials.
Collapse
Affiliation(s)
- D C Marshall
- Icahn School of Medicine at Mount Sinai, New York, NY
| | - A Shim
- New York Proton Center, New York, NY
| | - C C Chen
- New York Proton Center, New York, NY
| | - H Lin
- New York Proton Center, New York, NY
| | - F Yu
- New York Proton Center, New York, NY
| | - P Argiriadi
- Icahn School of Medicine at Mount Sinai, Department of Radiology, New York, NY
| | - I J Choi
- New York Proton Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY
| | - A M Chhabra
- New York Proton Center, New York, NY; Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
| | - C B Simone
- New York Proton Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY
| |
Collapse
|
18
|
Tu G, Peng W, Peng X, Zhao Z, Shi S, Cai Q, He B, Yin W, Peng S, Wang L, Yu F, Wang X. hsa_circ_0000519 promotes the progression of lung adenocarcinoma through the hsa-miR-1296-5p/DARS axis. Am J Cancer Res 2023; 13:3342-3367. [PMID: 37693148 PMCID: PMC10492121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2023] [Accepted: 07/18/2023] [Indexed: 09/12/2023] Open
Abstract
Emerging research indicates that circRNAs serve a crucial role in occurrence and development of cancers. This study aimed to uncover the biological role of hsa_circ_0000519 in the progression of LUAD (lung adenocarcinoma). hsa_circ_0000519 was identified by bioinformatic analysis, and its differential expression was validated in LUAD tissues and cell lines. CCK8, colony formation, wound healing, transwell assays, and xenograft tumor models were used to observe the biological functions of hsa_circ_0000519. FISH, RIP, dual luciferase reporter assays, and recovery experiments were implemented to explore the underlying mechanisms of hsa_circ_0000519. hsa_circ_0000519 was significantly upregulated in LUAD tissues and cell lines. The expression of hsa_circ_0000519 was positively correlated with T grade and TNM stage in patients with LUAD. Downregulation of hsa_circ_0000519 remarkably reduced cell proliferation, migration, invasion in vitro, and tumor growth in vivo. Mechanistic investigation demonstrated that hsa_circ_0000519 directly sponged hsa-miR-1296-5p to reduce its repressive impact on DARS as well as activate the PI3K/AKT/mTOR signaling pathway. The malignant phenotypes of LUAD cells induced by upregulation of hsa_circ_0000519 could be rescued by hsa-miR-1296-5p overexpression or knockdown of DARS. In conclusion, hsa_circ_0000519 promotes LUAD progression through the hsa-miR-1296-5p/DARS axis and may be expected as a novel biomarker and therapeutic for LUAD.
Collapse
Affiliation(s)
- Guangxu Tu
- Department of Thoracic Surgery, The Second Xiangya Hospital, Central South UniversityChangsha 410011, Hunan, China
- Hunan Key Laboratory of Early Diagnosis and Precision Therapy, The Second Xiangya Hospital, Central South UniversityChangsha 410011, Hunan, China
| | - Weilin Peng
- Department of Thoracic Surgery, The Second Xiangya Hospital, Central South UniversityChangsha 410011, Hunan, China
- Hunan Key Laboratory of Early Diagnosis and Precision Therapy, The Second Xiangya Hospital, Central South UniversityChangsha 410011, Hunan, China
| | - Xiong Peng
- Department of Thoracic Surgery, The Second Xiangya Hospital, Central South UniversityChangsha 410011, Hunan, China
- Hunan Key Laboratory of Early Diagnosis and Precision Therapy, The Second Xiangya Hospital, Central South UniversityChangsha 410011, Hunan, China
| | - Zhenyu Zhao
- Department of Thoracic Surgery, The Second Xiangya Hospital, Central South UniversityChangsha 410011, Hunan, China
- Hunan Key Laboratory of Early Diagnosis and Precision Therapy, The Second Xiangya Hospital, Central South UniversityChangsha 410011, Hunan, China
| | - Shuai Shi
- Department of Thoracic Surgery, The Second Xiangya Hospital, Central South UniversityChangsha 410011, Hunan, China
- Hunan Key Laboratory of Early Diagnosis and Precision Therapy, The Second Xiangya Hospital, Central South UniversityChangsha 410011, Hunan, China
| | - Qidong Cai
- Department of Thoracic Surgery, The Second Xiangya Hospital, Central South UniversityChangsha 410011, Hunan, China
- Hunan Key Laboratory of Early Diagnosis and Precision Therapy, The Second Xiangya Hospital, Central South UniversityChangsha 410011, Hunan, China
| | - Boxue He
- Department of Thoracic Surgery, The Second Xiangya Hospital, Central South UniversityChangsha 410011, Hunan, China
- Hunan Key Laboratory of Early Diagnosis and Precision Therapy, The Second Xiangya Hospital, Central South UniversityChangsha 410011, Hunan, China
| | - Wei Yin
- Department of Thoracic Surgery, The Second Xiangya Hospital, Central South UniversityChangsha 410011, Hunan, China
- Hunan Key Laboratory of Early Diagnosis and Precision Therapy, The Second Xiangya Hospital, Central South UniversityChangsha 410011, Hunan, China
| | - Shaoliang Peng
- College of Computer Science and Electronic Engineering, Hunan UniversityChangsha 410082, Hunan, China
- School of Computer Science, National University of Defense TechnologyChangsha 410073, Hunan, China
| | - Li Wang
- Department of Thoracic Surgery, The Second Xiangya Hospital, Central South UniversityChangsha 410011, Hunan, China
- Hunan Key Laboratory of Early Diagnosis and Precision Therapy, The Second Xiangya Hospital, Central South UniversityChangsha 410011, Hunan, China
| | - Fenglei Yu
- Department of Thoracic Surgery, The Second Xiangya Hospital, Central South UniversityChangsha 410011, Hunan, China
- Hunan Key Laboratory of Early Diagnosis and Precision Therapy, The Second Xiangya Hospital, Central South UniversityChangsha 410011, Hunan, China
| | - Xiang Wang
- Department of Thoracic Surgery, The Second Xiangya Hospital, Central South UniversityChangsha 410011, Hunan, China
- Hunan Key Laboratory of Early Diagnosis and Precision Therapy, The Second Xiangya Hospital, Central South UniversityChangsha 410011, Hunan, China
| |
Collapse
|
19
|
Pan L, Xue H, Yu F, Shan D, Zhang DP, Wang JJ. [Status and associated factors of pre-exposure prophylaxis use among men who have sex with men in 24 cities in China]. Zhonghua Liu Xing Bing Xue Za Zhi 2023; 44:905-911. [PMID: 37380411 DOI: 10.3760/cma.j.cn112338-20220831-00749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 06/30/2023]
Abstract
Objective: To understand the cognition and medication use of pre-exposure prophylaxis (PrEP) among men who have sex with men (MSM) in China and its associated factors. Method: From August 25 to September 5, 2021, 2 447 MSM were recruited in 24 cities to complete the online questionnaire through a male social interaction platform, Blued 7.5 software. The survey contents included demographic information of the respondents, PrEP awareness and usage, and risk behaviors. Descriptive analysis and multi-level logistic regression were performed for data analysis. SPSS 24.0 and SAS 9.4 software were used for statistical analysis. Results: Among the 2 447 respondents of MSM, 1 712 (69.96%) had heard of PrEP, 437 (17.86%) ever used PrEP, 274 (11.20%) were on PrEP, and 163 (6.66%) had discontinued PrEP; among the 437 cases (whoever used PrEP), more than 61.88% (388/627) adopted emtricitabine/tenofovir disoproxil fumarate regimen, and most of them adopted on-demand regimen. The average PrEP dosage reported in the past year is 1.12 tabletsper person per week. PrEP purchase was primarily via an online channel, and the most concerned factor was the PrEP effectiveness on HIV prevention. The most common reasons for discontinuing PrEP, reported by 163 cases, were the lack of HIV risk perception, the use of a condom to prevent HIV, and the economic burden of PrEP use. The logistic regression analysis showed that PrEP use among MSM in 24 cities was statistically associated with age, monthly income, ever having unprotected anal sex in the past year, used sexual drugs and sexually transmitted disease (STD) diagnosis in the past year. Compared with MSM aged 18-24, the proportion of MSM was relatively lower among those aged 25-44, who discontinued the PrEP (aOR=0.54,95%CI:0.34-0.87) or never used PrEP (aOR=0.62,95%CI:0.44-0.87). The proportion of unprotected anal sex among MSM currently on PrEP use was higher than those who have stopped PrEP and never used PrEP (all P<0.05). Those MSM group, with monthly income higher than 5 000 Yuan, used sexual drugs and STD diagnosis in the past year were more likely to have a higher rate for PrEP usage (all P<0.05). Conclusions: Currently, pre-exposure prophylaxis in the MSM group is primarily obtained via the online channel and adopted in an on-demand mode. Although the PrEP users have reached a certain proportion, it is still necessary to strengthen health education on the PrEP effects and side effects of MSM and to improve the awareness and use rate, especially for young MSM group, which can be combined with the advantages of the internet targeting its needs and use barriers.
Collapse
Affiliation(s)
- L Pan
- National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - H Xue
- Danlan Goodness, Beijing 100022, China
| | - F Yu
- Danlan Goodness, Beijing 100022, China
| | - D Shan
- National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - D P Zhang
- National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - J J Wang
- National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| |
Collapse
|
20
|
Liu Y, Luo X, Liu J, Ma Y, Tan J, Wang W, Hu J, Fu X, Xu L, Yu F, Xu S, Ma H, Yu X, You Q, Wang Z, Li L, Zhang X, Sun X. Shenlingcao oral liquid for patients with non-small cell lung cancer receiving adjuvant chemotherapy after radical resection: A multicenter randomized controlled trial. Phytomedicine 2023; 113:154723. [PMID: 36871476 DOI: 10.1016/j.phymed.2023.154723] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/02/2022] [Revised: 01/20/2023] [Accepted: 02/19/2023] [Indexed: 06/18/2023]
Abstract
BACKGROUND Low quality of life (QoL) in patients with non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy after radical resection is a major global health issue. High-quality evidence for the effectiveness of Shenlingcao oral liquid (SOL) as a complementary treatment in this patients is lacking at present. PURPOSE To determine whether complementary SOL treatment in NSCLC patients receiving adjuvant chemotherapy would yield greater improvements in QoL than chemotherapy alone. STUDY DESIGN We conducted a multicenter, randomized controlled trial of stages IIA-IIIA NSCLC patients undergoing adjuvant chemotherapy in seven hospitals. METHODS Using stratified blocks, participants were randomized in a 1:1 ratio to receive SOL combined with conventional chemotherapy or conventional chemotherapy alone. The primary outcome was the change in global QoL from baseline to the fourth chemotherapy cycle, and intention-to-treat analysis was applied with a mixed-effect model. Secondary outcomes were functional QoL, symptoms, and performance status scores at the 6-month follow-up. Missing data were handled with multiple imputation and a pattern-mixture model. RESULTS Among 516 randomized patients, 446 (86.43%) completed the study. After the fourth chemotherapy cycle, in comparison with the control group, patients receiving SOL showed a lower reduction in mean global QoL (-2.76 vs. -14.11; mean difference [MD], 11.34; 95% confidence interval [CI], 8.28 to 14.41), greater improvement in physical function (MD, 11.61; 95% CI, 8.57 to 14.65), role function (MD, 10.15; 95% CI, 5.75 to 14.54), and emotional function (MD, 4.71; 95% CI, 1.85 to 7.57), and greater improvements in lung cancer-related symptoms (e.g., fatigue, nausea/vomiting, and appetite loss) and performance status during the 6-month follow-up period (treatment main effect, p < 0.05). CONCLUSION SOL treatment for NSCLC patients receiving adjuvant chemotherapy can significantly improve QoL and performance status within 6 months after radical resection. TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT03712969.
Collapse
Affiliation(s)
- Yanmei Liu
- Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, China; NMPA Key Laboratory for Real World Data Research and Evaluation in Hainan, Chengdu, China; Sichuan Center of Technology Innovation for Real World Data, Chengdu, China
| | - Xiaochao Luo
- Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, China; NMPA Key Laboratory for Real World Data Research and Evaluation in Hainan, Chengdu, China; Sichuan Center of Technology Innovation for Real World Data, Chengdu, China
| | - Jiali Liu
- Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, China; NMPA Key Laboratory for Real World Data Research and Evaluation in Hainan, Chengdu, China; Sichuan Center of Technology Innovation for Real World Data, Chengdu, China
| | - Yu Ma
- Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, China; NMPA Key Laboratory for Real World Data Research and Evaluation in Hainan, Chengdu, China; Sichuan Center of Technology Innovation for Real World Data, Chengdu, China
| | - Jing Tan
- Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, China; NMPA Key Laboratory for Real World Data Research and Evaluation in Hainan, Chengdu, China; Sichuan Center of Technology Innovation for Real World Data, Chengdu, China
| | - Wen Wang
- Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, China; NMPA Key Laboratory for Real World Data Research and Evaluation in Hainan, Chengdu, China; Sichuan Center of Technology Innovation for Real World Data, Chengdu, China
| | - Jian Hu
- Department of Thoracic Surgery, The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou 310003, China
| | - Xiangning Fu
- Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
| | - Lin Xu
- Department of Thoracic Surgery, Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing 210029, China
| | - Fenglei Yu
- Department of Thoracic Surgery, The Second Xiangya Hospital, Central South University, Changsha 410011, China
| | - Shidong Xu
- Department of Thoracic Surgery, Harbin Medical University Cancer Hospital, Harbin 150081, China
| | - Haitao Ma
- Department of Thoracic Surgery, Dushu Lake Hospital Affiliated to Soochow University, Suzhou, Jiangsu 215006, China
| | - Xiuyi Yu
- Department of Thoracic Surgery, The First Affiliated Hospital of Xiamen University, Xiamen 361003, China
| | - Qingjun You
- Department of Thoracic Surgery, The Affiliated Hospital of Jiangnan University, Wuxi 214062, China
| | - Zhiqiang Wang
- Department of Thoracic Surgery, The Affiliated Hospital of Jiangnan University, Wuxi 214062, China
| | - Ling Li
- Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, China; NMPA Key Laboratory for Real World Data Research and Evaluation in Hainan, Chengdu, China; Sichuan Center of Technology Innovation for Real World Data, Chengdu, China.
| | - Xun Zhang
- Department of Thoracic Surgery, Tianjin Chest Hospital, Tianjin 300051, China.
| | - Xin Sun
- Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, China; NMPA Key Laboratory for Real World Data Research and Evaluation in Hainan, Chengdu, China; Sichuan Center of Technology Innovation for Real World Data, Chengdu, China.
| |
Collapse
|
21
|
Zhou D, Yao T, Huang X, Wu F, Jiang Y, Peng M, Qian B, Liu W, Yu F, Chen C. Real-world comprehensive diagnosis and "Surgery + X" treatment strategy of early-stage synchronous multiple primary lung cancer. Cancer Med 2023. [PMID: 37081738 DOI: 10.1002/cam4.5972] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2023] [Revised: 03/31/2023] [Accepted: 04/08/2023] [Indexed: 04/22/2023] Open
Abstract
BACKGROUND Diagnosing and treating synchronous multiple primary lung cancers (sMPLC) are complex and challenging. This study aimed to report real-world data on the comprehensive diagnosis and treatment of patients with early-stage sMPLC. MATERIALS AND METHODS A single-center cohort study was carried out and a large number of patients with early-stage sMPLC were included. A single- or two-stage surgery was performed to remove the primary and co-existing lesions. The "X" strategies, including ablation, SBRT, and EGFR-TKIs treatment, were applied to treat the high-risk residual lesions. Wide panel-genomic sequencing was performed to assess the genetic heterogeneity of the co-existing lesions. RESULTS A total of 465 early-stage sMPLC patients with 1198 resected lesions were included. Despite most patients being histologically different or harboring different genetic alternations, about 7.5% of the patients had the same histological type and driver gene mutation changes, comprehensive re-evaluation is thus needed. The "Surgery + X" strategy showed remarkable efficacy and safety in treating multiple lesions. Follow-up data revealed that the T2 stage (p = 0.014) and the solid presence of a primary lesion (p < 0.001) were significantly related to tumor recurrence. And a T2-stage primary tumor had a significantly higher rate of developing new lesions after the initial surgery (p < 0.001). CONCLUSIONS In real-world practice, histopathological and radiological evaluation combined with genetic analyses could be a robust diagnostic approach for sMPLC. The "Surgery + X" treatment strategy showed remarkable efficacy, superiority, and safety in the clinical treatment of early-stage sMPLC.
Collapse
Affiliation(s)
- Danting Zhou
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, P.R. China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, P.R. China
| | - Tianyu Yao
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, P.R. China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, P.R. China
| | - Xiaojie Huang
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, P.R. China
| | - Fang Wu
- Department of Oncology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, P.R. China
| | - Yi Jiang
- Department of Pathology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, P.R. China
| | - Muyun Peng
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, P.R. China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, P.R. China
| | - Banglun Qian
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, P.R. China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, P.R. China
| | - Wenliang Liu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, P.R. China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, P.R. China
| | - Fenglei Yu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, P.R. China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, P.R. China
| | - Chen Chen
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, P.R. China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, P.R. China
| |
Collapse
|
22
|
Abstract
As a crucial source of mesenchymal stromal cells, CD51+/PDGFR-α+ human dental pulp stromal cells (hDPSCs) are promising seeding cells for regenerative medicine. Cellular senescence hinders the translational application of hDPSCs. However, it remains unclear whether chronological and replicative senescence results in distinct outcomes for hDPSCs. To investigate the influence of senescence on DPSCs, we used transgenic lineage tracking, immunofluorescence, flow cytometry, and various molecular experiments to depict the dynamic pattern of hDPSCs in mice and humans during chronological and replicative senescence. The data demonstrated that CD51+/PDGFR-α+ cells were decreased in chronological senescence. Impaired self-renewal and higher ossificatory differentiation were observed in chronologically senescent hDPSCs. Regarding replicative senescence, a decreased CD51+ but upregulated PDGFR-α+ population was observed in culture. Furthermore, weakened self-renewal and osteogenic differentiation were observed in replicatively senescent hDPSCs. In summary, CD51+/PDGFR-α+ hDPSCs decrease in chronologically aged pulp, with self-renewal that is impaired without impaired osteogenic differentiation. However, replicative senescence has a different impact: self-renewal and ossific differentiation are impaired and CD51 expression is reduced, but PDGFR-α expression remains. These findings demonstrate the different outcomes of chronological and replicative senescence in CD51+/PDGFR-α+ hDPSCs. Furthermore, we revealed that impaired self-renewal is the core dysfunction for both types of cellular aging and that osteogenic differentiation capability differs between them. This study provides insights into the influence of chronological and replicative senescence on the characteristics and capabilities of hDPSCs. These advances provide fundamental knowledge to alleviate cellular aging of CD51+/PDGFR-α+ hDPSCs and promote their translational applications.
Collapse
Affiliation(s)
- L Yao
- State Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China.,Department of Endodontics, West China Hospital of Stomatology, Sichuan University, Chengdu, China
| | - F Li
- State Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China
| | - C Yu
- State Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China.,Department of Endodontics, West China Hospital of Stomatology, Sichuan University, Chengdu, China
| | - H Wang
- State Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China
| | - Y Wang
- State Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China
| | - L Ye
- State Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China.,Department of Endodontics, West China Hospital of Stomatology, Sichuan University, Chengdu, China
| | - F Yu
- State Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China.,Department of Endodontics, West China Hospital of Stomatology, Sichuan University, Chengdu, China
| |
Collapse
|
23
|
Chi L, Wang H, Yu F, Gao C, Dai H, Si X, Liu L, Wang Z, Zheng J, Ke Y, Liu H, Zhang Q. Recent Progress of Ubiquitin-Specific-Processing Protease 7 Inhibitors. Russ J Bioorg Chem 2023. [DOI: 10.1134/s1068162023020073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/24/2023]
|
24
|
Wang B, Zhang Z, Guo Y, Yu F. Trachea repair using an autologous pericardial patch combined with a 3D carbon fiber stent: A case report. Front Surg 2023; 9:1086792. [PMID: 36700013 PMCID: PMC9869265 DOI: 10.3389/fsurg.2022.1086792] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2022] [Accepted: 12/05/2022] [Indexed: 01/12/2023] Open
Abstract
This study is the first to use an autologous pericardial patch combined with a 3D carbon fiber stent for the plastic repair of a large trachea defect. Radical surgery is the optimal therapy for primary malignant tracheal tumors. Tracheoplasty or repair is required to guarantee trachea integrity and normal ventilation function after tracheal tumor resection. Here, we present a case of plastic repair of the trachea using an autologous pericardial patch and a 3D custom-made carbon fiber stent. A 4 cm trachea defect was successfully repaired after resecting a malignant schwannoma. The postoperative ventilatory function was normal without obvious symptoms of discomfort. Fiberoptic bronchoscopy showed a smooth mucosal surface of the endotracheal wall and patency of the airway. CT scans performed 3 years after surgery showed no recurrence. Therefore, we can conclude that a 3D carbon fiber stent is feasible for abolishing patch floating and preventing tracheal stenosis.
Collapse
Affiliation(s)
- Bin Wang
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China,Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China,Early-Stage Lung Cancer Center, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Zhe Zhang
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China,Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China,Early-Stage Lung Cancer Center, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Yuanwei Guo
- Health Management Center, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Fenglei Yu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China,Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China,Early-Stage Lung Cancer Center, The Second Xiangya Hospital of Central South University, Changsha, China,Correspondence: Fenglei Yu
| |
Collapse
|
25
|
Yu F, Huang X, Zhou D, Zhao Z, Wu F, Qian B, Wang Q, Chen J, Liang Q, Jiang Y, Ding Q, He Q, Tang J, Wang X, Liu W, Chen C. Genetic, DNA methylation, and immune profile discrepancies between early-stage single primary lung cancer and synchronous multiple primary lung cancer. Clin Epigenetics 2023; 15:4. [PMID: 36611170 PMCID: PMC9824942 DOI: 10.1186/s13148-023-01422-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2022] [Accepted: 01/04/2023] [Indexed: 01/09/2023] Open
Abstract
BACKGROUND To explore the possible carcinogenesis and help better diagnose and treat patients with synchronous multiple primary lung cancers (sMPLC), we systematically investigated the genetic and DNA methylation profiles of early-stage sMPLC and single primary lung cancer (SPLC) and explored the immune profiles in the tumor microenvironment. METHODS Hundred and ninety-one patients with 191 nodules in the SPLC group and 132 patients with 295 nodules in the sMPLC group were enrolled. All the samples were subjected to wide panel-genomic sequencing. Genome-wide DNA methylation was assessed using the Infinium Human Methylation 850 K BeadChip. RNA-seq and CIBERSORT analyses were performed to identify the immune characteristics in these two groups. RESULTS Lesions from sMPLC patients had lower TMB levels than that from SPLC patients. sMPLC had a similar genetic mutational landscape with SPLC, despite some subgroup genetic discrepancies. Distinct DNA methylation patterns were identified between the two groups. The differentially methylated genes were related to immune response pathways. RNA-seq analyses revealed more immune-related DEGs in sMPLC. Accordingly, more immune-related biological processes and pathways were identified in sMPLC. Aberrant DNA methylation was associated with the abnormal expression of immune-related genes. CIBERSORT analysis revealed the infiltration of immune cells was different between the two groups. CONCLUSION Our study for the first time demonstrated genetic, epigenetic, and immune profile discrepancies between sMPLC and SPLC. Relative to the similar genetic mutational landscape, the DNA methylation patterns and related immune profiles were significantly different between sMPLC and SPLC, indicating their essential roles in the initiation and development of sMPLC.
Collapse
Affiliation(s)
- Fenglei Yu
- grid.452708.c0000 0004 1803 0208Department of Thoracic Surgery, Second Xiangya Hospital of Central South University, Changsha, 410011 Hunan People’s Republic of China ,grid.452708.c0000 0004 1803 0208Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, Second Xiangya Hospital of Central South University, Changsha, People’s Republic of China
| | - Xiaojie Huang
- grid.452708.c0000 0004 1803 0208Department of Cardiovascular Surgery, Second Xiangya Hospital of Central South University, Changsha, Hunan People’s Republic of China
| | - Danting Zhou
- grid.452708.c0000 0004 1803 0208Department of Thoracic Surgery, Second Xiangya Hospital of Central South University, Changsha, 410011 Hunan People’s Republic of China ,grid.452708.c0000 0004 1803 0208Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, Second Xiangya Hospital of Central South University, Changsha, People’s Republic of China
| | - Zhenyu Zhao
- grid.452708.c0000 0004 1803 0208Department of Thoracic Surgery, Second Xiangya Hospital of Central South University, Changsha, 410011 Hunan People’s Republic of China ,grid.452708.c0000 0004 1803 0208Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, Second Xiangya Hospital of Central South University, Changsha, People’s Republic of China
| | - Fang Wu
- grid.452708.c0000 0004 1803 0208Department of Oncology, Second Xiangya Hospital of Central South University, Changsha, Hunan People’s Republic of China
| | - Banglun Qian
- grid.452708.c0000 0004 1803 0208Department of Thoracic Surgery, Second Xiangya Hospital of Central South University, Changsha, 410011 Hunan People’s Republic of China ,grid.452708.c0000 0004 1803 0208Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, Second Xiangya Hospital of Central South University, Changsha, People’s Republic of China
| | - Qiang Wang
- grid.452708.c0000 0004 1803 0208Department of Thoracic Surgery, Second Xiangya Hospital of Central South University, Changsha, 410011 Hunan People’s Republic of China ,grid.452708.c0000 0004 1803 0208Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, Second Xiangya Hospital of Central South University, Changsha, People’s Republic of China
| | - Juan Chen
- grid.452708.c0000 0004 1803 0208Department of Radiology, Second Xiangya Hospital of Central South University, Changsha, Hunan People’s Republic of China
| | - Qingchun Liang
- grid.452708.c0000 0004 1803 0208Department of Pathology, Second Xiangya Hospital of Central South University, Changsha, Hunan People’s Republic of China
| | - Yi Jiang
- grid.452708.c0000 0004 1803 0208Department of Pathology, Second Xiangya Hospital of Central South University, Changsha, Hunan People’s Republic of China
| | - Qi Ding
- grid.512993.5Geneplus-Beijing Institute, Beijing, People’s Republic of China
| | - Qiongzhi He
- grid.512993.5Geneplus-Beijing Institute, Beijing, People’s Republic of China
| | - Jingqun Tang
- grid.452708.c0000 0004 1803 0208Department of Thoracic Surgery, Second Xiangya Hospital of Central South University, Changsha, 410011 Hunan People’s Republic of China ,grid.452708.c0000 0004 1803 0208Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, Second Xiangya Hospital of Central South University, Changsha, People’s Republic of China
| | - Xiang Wang
- grid.452708.c0000 0004 1803 0208Department of Thoracic Surgery, Second Xiangya Hospital of Central South University, Changsha, 410011 Hunan People’s Republic of China ,grid.452708.c0000 0004 1803 0208Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, Second Xiangya Hospital of Central South University, Changsha, People’s Republic of China
| | - Wenliang Liu
- grid.452708.c0000 0004 1803 0208Department of Thoracic Surgery, Second Xiangya Hospital of Central South University, Changsha, 410011 Hunan People’s Republic of China ,grid.452708.c0000 0004 1803 0208Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, Second Xiangya Hospital of Central South University, Changsha, People’s Republic of China
| | - Chen Chen
- grid.452708.c0000 0004 1803 0208Department of Thoracic Surgery, Second Xiangya Hospital of Central South University, Changsha, 410011 Hunan People’s Republic of China ,grid.452708.c0000 0004 1803 0208Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, Second Xiangya Hospital of Central South University, Changsha, People’s Republic of China
| |
Collapse
|
26
|
Yang WY, He Y, Peng M, Zhang Z, Xie S, Wu Z, Hu Q, Yu F. Thermal ablation versus radiotherapy for inoperable stage III non-small cell lung cancer: a propensity score matching analysis. Int J Hyperthermia 2022; 40:2154577. [PMID: 36535924 DOI: 10.1080/02656736.2022.2154577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
OBJECTIVE To compare the survival benefits of thermal ablation (TA) and radiotherapy in inoperable patients with stage III non-small cell lung cancer (NSCLC). METHOD A retrospective analysis was conducted using the data from the Surveillance, Epidemiology, and End Results (SEER) program. Propensity score matching (PSM) was conducted to balance potential baseline confounding factors. Survival analyses were conducted using Kaplan-Meier and Cox regression methods. RESULTS The present study included 33,393 inoperable patients with stage III NSCLC, including 106 patients treated with TA and 33,287 patients treated with radiotherapy. No statistical difference in overall survival (OS) (p = .065) or cancer-specific survival (CSS) (p = .996) was found between the patients treated with TA and those treated with radiotherapy. Using 1:3 matching, a matched cohort of 420 patients (105 patients treated with TA, 315 patients treated with radiotherapy) was identified. The differences in OS (p = .177) and CSS (p = .605) were still not significant between the radiotherapy and TA groups after PSM. According to subgroup analyses, TA showed comparable survival benefits in almost all subgroups compared to radiotherapy. CONCLUSION For inoperable stage III NSCLC, the survival benefit of TA was comparable to radiotherapy. TA may be a potential therapeutic modality for inoperable stage III NSCLC.
Collapse
Affiliation(s)
- Wei-Yu Yang
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.,Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Yu He
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.,Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Muyun Peng
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.,Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Zhe Zhang
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.,Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Shouzhi Xie
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.,Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Zeyu Wu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.,Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Qikang Hu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.,Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Fenglei Yu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.,Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| |
Collapse
|
27
|
Yu F, Peng M, Bai J, Zhu X, Zhang B, Tang J, Liu W, Chen C, Wang X, Chen M, Tan S, Sun Y, Liang Q, Li J, Hu Y, Liao A, Hu H, He Y, Xiao X, Wang B, Xing G, Xu Y, Chen R, Xia X, Chen X. Comprehensive characterization of genomic and radiologic features reveals distinct driver patterns of RTK/RAS pathway in ground-glass opacity pulmonary nodules. Int J Cancer 2022; 151:2020-2030. [PMID: 36029220 PMCID: PMC9805018 DOI: 10.1002/ijc.34238] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2021] [Revised: 06/12/2022] [Accepted: 06/13/2022] [Indexed: 01/09/2023]
Abstract
Ground-glass opacity (GGO)-associated pulmonary nodules have been known as a radiologic feature of early-stage lung cancers and exhibit an indolent biological behavior. However, the correlation between driver genes and radiologic features as well as the immune microenvironment remains poorly understood. We performed a custom 1021-gene panel sequencing of 334 resected pulmonary nodules presenting as GGO from 262 Chinese patients. A total of 130 multiple pulmonary nodules were sampled from 58 patients. Clinical-pathologic and radiologic parameters of these pulmonary nodules were collected. Immunohistochemistry (IHC) and multiplex immunofluorescent staining (mIF) were applied to analyze proliferation and immune cell markers of GGO-associated pulmonary nodules. Compared with pure GGO nodules, mixed GGO nodules were enriched for invasive adenocarcinoma (IAC) (182/216 vs 73/118, P < .001). Eighty-eight percent (294/334) of GGO-associated nodules carried at least one mutation in EGFR/ERBB2/BRAF/KRAS/MAP2K1 of the RTK/RAS signaling pathway, and the alterations in these driver genes were mutually exclusive. The analysis of multifocal pulmonary nodules from the same patient revealed evidence of functional convergence on RTK/RAS pathways. Nodules with ERBB2/BRAF/MAP2K1 mutations tended to be more indolent than those with EGFR and KRAS mutations. IHC and mIF staining showed that KRAS-mutant GGO nodules displayed higher infiltration of CD4+ T cell and CD8+ T cell as well as stronger proliferation and immune inhibitory signals. Our study demonstrates a driver landscape of radiologically detectable GGO-associated pulmonary nodules in Chinese patients and supports that different driver patterns in RTK/RAS pathway are corresponding to different radiologic features.
Collapse
Affiliation(s)
- Fenglei Yu
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung CancerThe Second Xiangya Hospital of Central South UniversityChangshaChina,Department of Thoracic SurgeryThe Second Xiangya Hospital of Central South UniversityChangshaChina,Early‐Stage Lung Cancer CenterThe Second Xiangya Hospital of Central South UniversityChangshaChina
| | - Muyun Peng
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung CancerThe Second Xiangya Hospital of Central South UniversityChangshaChina,Department of Thoracic SurgeryThe Second Xiangya Hospital of Central South UniversityChangshaChina,Early‐Stage Lung Cancer CenterThe Second Xiangya Hospital of Central South UniversityChangshaChina
| | - Jing Bai
- Geneplus‐Beijing InstitutePeking University Medical Industrial ParkBeijingChina
| | - Xiuli Zhu
- Geneplus‐Beijing InstitutePeking University Medical Industrial ParkBeijingChina
| | - Bingyu Zhang
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung CancerThe Second Xiangya Hospital of Central South UniversityChangshaChina,Department of Thoracic SurgeryThe Second Xiangya Hospital of Central South UniversityChangshaChina,Early‐Stage Lung Cancer CenterThe Second Xiangya Hospital of Central South UniversityChangshaChina
| | - Jingqun Tang
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung CancerThe Second Xiangya Hospital of Central South UniversityChangshaChina,Department of Thoracic SurgeryThe Second Xiangya Hospital of Central South UniversityChangshaChina,Early‐Stage Lung Cancer CenterThe Second Xiangya Hospital of Central South UniversityChangshaChina
| | - Wenliang Liu
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung CancerThe Second Xiangya Hospital of Central South UniversityChangshaChina,Department of Thoracic SurgeryThe Second Xiangya Hospital of Central South UniversityChangshaChina,Early‐Stage Lung Cancer CenterThe Second Xiangya Hospital of Central South UniversityChangshaChina
| | - Chen Chen
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung CancerThe Second Xiangya Hospital of Central South UniversityChangshaChina,Department of Thoracic SurgeryThe Second Xiangya Hospital of Central South UniversityChangshaChina,Early‐Stage Lung Cancer CenterThe Second Xiangya Hospital of Central South UniversityChangshaChina
| | - Xiang Wang
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung CancerThe Second Xiangya Hospital of Central South UniversityChangshaChina,Department of Thoracic SurgeryThe Second Xiangya Hospital of Central South UniversityChangshaChina,Early‐Stage Lung Cancer CenterThe Second Xiangya Hospital of Central South UniversityChangshaChina
| | - Mingjiu Chen
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung CancerThe Second Xiangya Hospital of Central South UniversityChangshaChina,Department of Thoracic SurgeryThe Second Xiangya Hospital of Central South UniversityChangshaChina,Early‐Stage Lung Cancer CenterThe Second Xiangya Hospital of Central South UniversityChangshaChina
| | - Sichuang Tan
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung CancerThe Second Xiangya Hospital of Central South UniversityChangshaChina,Department of Thoracic SurgeryThe Second Xiangya Hospital of Central South UniversityChangshaChina,Early‐Stage Lung Cancer CenterThe Second Xiangya Hospital of Central South UniversityChangshaChina
| | - Yi Sun
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung CancerThe Second Xiangya Hospital of Central South UniversityChangshaChina,Department of PathologyThe Second Xiangya Hospital of Central South UniversityChangshaChina
| | - Qingchun Liang
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung CancerThe Second Xiangya Hospital of Central South UniversityChangshaChina,Department of PathologyThe Second Xiangya Hospital of Central South UniversityChangshaChina
| | - Jina Li
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung CancerThe Second Xiangya Hospital of Central South UniversityChangshaChina,Department of Thoracic SurgeryThe Second Xiangya Hospital of Central South UniversityChangshaChina,Early‐Stage Lung Cancer CenterThe Second Xiangya Hospital of Central South UniversityChangshaChina
| | - Yan Hu
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung CancerThe Second Xiangya Hospital of Central South UniversityChangshaChina,Department of Thoracic SurgeryThe Second Xiangya Hospital of Central South UniversityChangshaChina,Early‐Stage Lung Cancer CenterThe Second Xiangya Hospital of Central South UniversityChangshaChina
| | - Aihui Liao
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung CancerThe Second Xiangya Hospital of Central South UniversityChangshaChina,Department of General SurgeryHunan Geological and Mineral HospitalChangshaChina
| | - Huali Hu
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung CancerThe Second Xiangya Hospital of Central South UniversityChangshaChina,Department of General SurgeryHunan Geological and Mineral HospitalChangshaChina
| | - Yu He
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung CancerThe Second Xiangya Hospital of Central South UniversityChangshaChina,Department of Thoracic SurgeryThe Second Xiangya Hospital of Central South UniversityChangshaChina,Early‐Stage Lung Cancer CenterThe Second Xiangya Hospital of Central South UniversityChangshaChina
| | - Xiao Xiao
- Geneplus‐ShenzhenShenzhenGuangdong ProvinceChina
| | - Bin Wang
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung CancerThe Second Xiangya Hospital of Central South UniversityChangshaChina,Department of Thoracic SurgeryThe Second Xiangya Hospital of Central South UniversityChangshaChina,Early‐Stage Lung Cancer CenterThe Second Xiangya Hospital of Central South UniversityChangshaChina
| | - Guanlan Xing
- Geneplus‐Beijing InstitutePeking University Medical Industrial ParkBeijingChina
| | - Yaping Xu
- Geneplus‐Beijing InstitutePeking University Medical Industrial ParkBeijingChina
| | - Rongrong Chen
- Geneplus‐Beijing InstitutePeking University Medical Industrial ParkBeijingChina
| | - Xuefeng Xia
- Geneplus‐Beijing InstitutePeking University Medical Industrial ParkBeijingChina
| | - Xiaofeng Chen
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung CancerThe Second Xiangya Hospital of Central South UniversityChangshaChina,Early‐Stage Lung Cancer CenterThe Second Xiangya Hospital of Central South UniversityChangshaChina,Department of AnesthesiaThe Second Xiangya Hospital of Central South UniversityChangshaChina
| |
Collapse
|
28
|
Peng X, Yang R, Peng W, Zhao Z, Tu G, He B, Cai Q, Shi S, Yin W, Yu F, Tao Y, Wang X. Overexpression of LINC00551 promotes autophagy-dependent ferroptosis of lung adenocarcinoma via upregulating DDIT4 by sponging miR-4328. PeerJ 2022; 10:e14180. [PMID: 36570007 PMCID: PMC9772902 DOI: 10.7717/peerj.14180] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2022] [Accepted: 09/13/2022] [Indexed: 12/27/2022] Open
Abstract
According to mounting evidence, long noncoding RNAs (lncRNAs) play a vital role in regulated cell death (RCD). A potential strategy for cancer therapy involves triggering ferroptosis, a novel form of RCD. Although it is thought to be an autophagy-dependent process, it is still unclear how the two processes interact. This study characterized a long intergenic noncoding RNA, LINC00551, expressed at a low level in lung adenocarcinoma (LUAD) and some other cancers. Overexpression of LINC00551 suppresses cell viability while promoting autophagy and RSL-3-induced ferroptosis in LUAD cells. LINC00551 acts as a competing endogenous RNA (ceRNA) and binds with miR-4328 which up-regulates the target DNA damage-inducible transcript 4 (DDIT4). DDIT4 inhibits the activity of mTOR, promotes LUAD autophagy, and then promotes the ferroptosis of LUAD cells in an autophagy-dependent manner. This study provided an insight into the molecular mechanism regulating ferroptosis and highlighted LINC00551 as a potential therapeutic target for LUAD.
Collapse
Affiliation(s)
- Xiong Peng
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China,Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, the Second Xiangya Hospital of Central South University, Changsha, Hunan, China
| | - Rui Yang
- Department of Pathology, School of Basic Medicine and Xiangya Hospital, Central South University, Changsha, Hunan, China
| | - Weilin Peng
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China,Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, the Second Xiangya Hospital of Central South University, Changsha, Hunan, China
| | - Zhenyu Zhao
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China,Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, the Second Xiangya Hospital of Central South University, Changsha, Hunan, China
| | - Guangxu Tu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China,Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, the Second Xiangya Hospital of Central South University, Changsha, Hunan, China
| | - Boxue He
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China,Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, the Second Xiangya Hospital of Central South University, Changsha, Hunan, China
| | - Qidong Cai
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China,Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, the Second Xiangya Hospital of Central South University, Changsha, Hunan, China
| | - Shuai Shi
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China,Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, the Second Xiangya Hospital of Central South University, Changsha, Hunan, China
| | - Wei Yin
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China,Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, the Second Xiangya Hospital of Central South University, Changsha, Hunan, China
| | - Fenglei Yu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China,Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, the Second Xiangya Hospital of Central South University, Changsha, Hunan, China
| | - Yongguang Tao
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China,NHC Key Laboratory of Carcinogenesis (Central South University), Cancer Research Institute and School of Basic Medicine, Central South University, Changsha, Hunan, China,Department of Pathology, Xiangya Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Central South University, Changsha, Hunan, China
| | - Xiang Wang
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China,Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, the Second Xiangya Hospital of Central South University, Changsha, Hunan, China
| |
Collapse
|
29
|
Yu F, Jiang YM. [Research advances in the application of bone metabolic markers in children's diseases associated with growth and development]. Zhonghua Yu Fang Yi Xue Za Zhi 2022; 56:1226-1231. [PMID: 36207884 DOI: 10.3760/cma.j.cn112150-20220610-00596] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
The incidence of children's growth and development diseases such as rickets, obesity, dwarfism and precocious puberty has increased year by year recently. The occurrence and development of these diseases are often closely related to children's malnutrition and endocrine disorders. Plenty of studies have indicated that bone is not only the structural scaffold of human body, but also an important endocrine and hormone target organ. As a series of substances closely related to bone formation and bone resorption, the levels of bone metabolic markers have been confirmed to change in the course of many children's growth and development diseases. The characteristics, classification and application of bone metabolism markers in children's growth and development related diseases was summarized and commented in this article in order to provide reference for the prevention, early diagnosis and treatment effect monitoring of children's growth and development diseases.
Collapse
Affiliation(s)
- F Yu
- Department of Laboratory Medicine, West China Second University Hospital, Sichuan University, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu 610041, China
| | - Y M Jiang
- Department of Laboratory Medicine, West China Second University Hospital, Sichuan University, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu 610041, China
| |
Collapse
|
30
|
Liang W, Cai K, Cao Q, Chen C, Chen H, Chen J, Chen KN, Chen Q, Chu T, Dong Y, Fan J, Fang W, Fu J, Fu X, Gao S, Ge D, Geng G, Geng Q, He J, Hu J, Hu J, Hu WD, Jiang F, Jiang T, Jiao W, Li HC, Li Q, Li S, Li S, Li X, Liao YD, Liu C, Liu H, Liu Y, Lu Z, Luo Q, Ma H, Pan X, Qiao G, Ren S, Shen W, Song Y, Sun D, Wang G, Wang J, Wang M, Wang Q, Wang WX, Wei L, Wu M, Wu N, Xia H, Xu SD, Yang F, Yang K, Yang Y, Yu F, Yu ZT, Yue DS, Zhang L, Zhang W, Zhang Z, Zhao G, Zhao J, Zhao X, Zhou C, Zhou Q, Zhu K, Zhu Y, Hida T, Dempke WCM, Rossi A, de Perrot M, Ramirez RA, Provencio M, Lee JM, Passaro A, Spaggiari L, Spicer J, Girard N, Forde PM, Mok TSK, Cascone T, He J. International expert consensus on immunotherapy for early-stage non-small cell lung cancer. Transl Lung Cancer Res 2022; 11:1742-1762. [PMID: 36248334 PMCID: PMC9554679 DOI: 10.21037/tlcr-22-617] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2022] [Accepted: 09/26/2022] [Indexed: 02/05/2023]
Affiliation(s)
- Wenhua Liang
- Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, Guangzhou, China
| | - Kaican Cai
- Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China
| | - Qingdong Cao
- Department of Thoracic Surgery, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China
| | - Chun Chen
- Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, China
| | - Haiquan Chen
- Department of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China
| | - Jun Chen
- Department of Lung Cancer Surgery, Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, China
| | - Ke-Neng Chen
- Department of Thoracic Surgery, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
| | - Qixun Chen
- Department of Thoracic Surgery, Cancer Hospital of University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China
- Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Science, Hangzhou, China
| | - Tianqing Chu
- Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Yuchao Dong
- Department of Respiratory and Critical Care Medicine, Shanghai Changhai Hospital, The First Affiliated Hospital of Second Military Medical University, Shanghai, China
| | - Jiang Fan
- Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
- Department of Thoracic Surgery, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China
| | - Wentao Fang
- Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
| | - Junke Fu
- Department of Thoracic Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
| | - Xiangning Fu
- Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Shugeng Gao
- Thoracic Surgery Department, National Cancer Center–National Clinical Research Center for Cancer–Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Di Ge
- Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China
| | - Guojun Geng
- Department of Thoracic Surgery, Xiamen Key Laboratory of Thoracic Tumor Diagnosis and Treatment, Institute of Lung Cancer, The First Affiliated Hospital of Xiamen University, School of Clinical Medicine, Fujian Medical University, Xiamen, China
| | - Qing Geng
- Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, China
| | - Jie He
- Thoracic Surgery Department, National Cancer Center–National Clinical Research Center for Cancer–Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Jian Hu
- Department of Thoracic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Jie Hu
- Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China
| | - Wei-Dong Hu
- Department of Thoracic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - Feng Jiang
- Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, China
| | - Tao Jiang
- Department of Thoracic Surgery, Tangdu Hospital, Air Force Medical University, Xi’an, China
| | - Wenjie Jiao
- Department of Thoracic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China
| | - He-Cheng Li
- Department of Thoracic Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Qiang Li
- Department of Thoracic Surgery, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
| | - Shanqing Li
- Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Shuben Li
- Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, Guangzhou, China
| | - Xiangnan Li
- Department of Thoracic Surgery, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Yong-De Liao
- Department of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Changhong Liu
- Department of Thoracic Surgery, The Second Hospital of Dalian Medical University, Dalian, China
| | - Hongxu Liu
- Department of Thoracic Surgery, Cancer Hospital of China Medical University, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute, Shenyang, China
| | - Yang Liu
- Department of Thoracic Surgery, Chinese People’s Liberation Army General Hospital, Beijing, China
| | - Zhuming Lu
- Department of Cardiothoracic Surgery, Jiangmen Central Hospital, Jiangmen, China
| | - Qingquan Luo
- Department of Thoracic Surgery, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China
| | - Haitao Ma
- Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China
| | - Xiaojie Pan
- Department of Thoracic Surgery, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, FuzhouChina
| | - Guibin Qiao
- Division of Thoracic Surgery, Guangdong Provincial People’s Hospital & Guangdong Academy of Medical Sciences, The Second School of Clinical Medicine, Southern Medical University, Shantou University Medical College, Guangzhou, China
| | - Shengxiang Ren
- Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
| | - Weiyu Shen
- Department of Thoracic Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo University, Ningbo, China
| | - Yong Song
- Department of Respiratory Medicine, Jinling Hospital, Nanjing Medical University, Nanjing, China
| | - Daqiang Sun
- Department of Thoracic Surgery, Tianjin Chest Hospital, Tianjin, China
| | - Guangsuo Wang
- Department of Thoracic Surgery, The First Affiliated Hospital of Southern, University of Sciences and Technology, Shenzhen People’s Hospital, Shenzhen, China
| | - Jie Wang
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Mengzhao Wang
- Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China
| | - Qiwen Wang
- Department of Thoracic Oncosurgery, Jilin Province Tumor Hospital, Changchun, China
| | - Wen-Xiang Wang
- Department of Thoracic Surgery II, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, China
| | - Li Wei
- Department of Thoracic Surgery, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, People’s Hospital of Henan University, Zhengzhou, China
| | - Ming Wu
- Department of Thoracic Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Nan Wu
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Thoracic Surgery II, Peking University Cancer Hospital & Institute, Beijing, China
| | - Hui Xia
- Department of Cardiothoracic Surgery, The Fourth Medical Center of PLA General Hospital, Beijing, China
| | - Shi-Dong Xu
- Department of Thoracic Surgery, Harbin Medical University Cancer Hospital, Harbin, China
| | - Fan Yang
- Department of Thoracic Surgery, Peking University People’s Hospital, Beijing, China
| | - Kang Yang
- Department of Thoracic Surgery, GuiQian International General Hospital, Guiyang, China
| | - Yue Yang
- Department of Thoracic Surgery II, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China
| | - Fenglei Yu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Zhen-Tao Yu
- Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China
| | - Dong-Sheng Yue
- Department of Lung Cancer, Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, China
| | - Lanjun Zhang
- Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China
| | - Weidong Zhang
- Department of Thoracic Surgery, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China
| | - Zhenfa Zhang
- Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China
| | - Guofang Zhao
- Department of Thoracic Surgery, Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo, China
| | - Jian Zhao
- Department of Thoracic Surgery, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China
| | - Xiaojing Zhao
- Department of Thoracic Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Chengzhi Zhou
- State Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China
| | - Qinghua Zhou
- Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, China
| | - Kunshou Zhu
- Department of Thoracic Surgery, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, China
| | - Yuming Zhu
- Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China
| | - Toyoaki Hida
- Lung Cancer Center, Central Japan International Medical Center, Minokamo, Japan
| | - Wolfram C. M. Dempke
- Department of Hematology and Oncology, University Medical School, Munich, Germany
| | - Antonio Rossi
- Oncology Center of Excellence, Therapeutic Science & Strategy Unit, IQVIA, Milan, Italy
| | - Marc de Perrot
- Division of Thoracic Surgery, Toronto General Hospital and Princess Margaret Cancer Centre, Toronto, ON, Canada
| | - Robert A. Ramirez
- Department of Internal Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Mariano Provencio
- Service of Medical Oncology, Puerta del Hierro University Hospital of Madrid, Madrid, Spain
| | - Jay M. Lee
- Division of Thoracic Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
| | - Antonio Passaro
- Division of Medical Oncology, European Institute of Oncology IRCCS, Milan, Italy
| | - Lorenzo Spaggiari
- Department of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| | - Jonathan Spicer
- Division of Thoracic Surgery, Department of Surgery, McGill University Health Centre, Montreal, QC, Canada
| | - Nicolas Girard
- Thoracic Oncology Service, Thorax Institute Curie Montsouris, Institut Curie, Paris, France
| | - Patrick M. Forde
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA
| | - Tony S. K. Mok
- Department of Clinical Oncology, State Key Laboratory of South China, Chinese University of Hong Kong, Shatin, Hong Kong, China
| | - Tina Cascone
- Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Jianxing He
- Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, Guangzhou, China
| |
Collapse
|
31
|
Yang WY, He Y, Hu Q, Peng M, Zhang Z, Xie S, Yu F. Survival benefit of thermal ablation therapy for patients with stage II-III non-small cell lung cancer: A propensity-matched analysis. Front Oncol 2022; 12:984932. [PMID: 36081544 PMCID: PMC9446892 DOI: 10.3389/fonc.2022.984932] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2022] [Accepted: 08/03/2022] [Indexed: 11/15/2022] Open
Abstract
Background Thermal ablation (TA) is considered a safe alternative to surgical resection for the treatment of non-small cell lung cancer (NSCLC). While previous studies have shown that TA is beneficial for stage I NSCLC patients, however, few have reported on TA efficacy in patients with stage II-III NSCLC. The current study investigated the impact of TA on the overall survival (OS) and cancer-specific survival (CSS) of patients with stage II-III NSCLC. Methods Data on patients with stage II-III NSCLC who did not undergo surgical resection between 2004 and 2015 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Propensity score matching (PSM), Kaplan-Meier survival curves, and Cox regression were used for statistical analyses. Results A total of 57,959 stage II-III NSCLC patients who did not undergo surgical resection were included in this study, 261 of whom received TA. Overall, TA was associated with a longer OS (p = 0.035) and CSS (p = 0.005) than non-ablation. After 1:3 PSM, 252 patients receiving TA and 732 patients not receiving ablation were enrolled in the matched cohort. The OS (p = 0.047) and CSS (p = 0.029) remained higher in the TA group than in the non-ablation group after PSM. Cox regression analysis showed that age, sex, primary tumor site, pathological type, tumor size, radiotherapy, chemotherapy, and thermal ablation were independently associated with OS and CSS (p <0.05). Subgroup analysis found that the advantages of TA were more pronounced among individuals ≥70 years of age, with tumor size ≤3.0 cm, or who did not receive radiotherapy. Conclusion TA could be an effective alternative treatment for stage II-III NSCLC patients unsuitable for surgical resection, particularly those ≥70 years of age, with tumor size ≤3.0 cm, or who have not received radiotherapy.
Collapse
Affiliation(s)
- Wei-Yu Yang
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Yu He
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Qikang Hu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Muyun Peng
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Zhe Zhang
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Shouzhi Xie
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Fenglei Yu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
- *Correspondence: Fenglei Yu,
| |
Collapse
|
32
|
Xie Y, Li C, Zhang L, Zang S, Yu F, Wang S, Wang F. [ 68Ga-PSMA-I&T PET/CT for assessment of tumor burden in primary lesions of treatmentnaïve prostate cancer]. Nan Fang Yi Ke Da Xue Xue Bao 2022; 42:1143-1148. [PMID: 36073212 DOI: 10.12122/j.issn.1673-4254.2022.08.05] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
OBJECTIVE To investigate the value of 68Ga-labeled prostate specific membrane antigen (PSMA) PET/CT for assessing tumor load in primary lesions for risk stratification and predicting metastasis of newly diagnosed prostate cancer (PCa). METHODS We retrospectively analyzed the data of 36 patients (mean age 71.3 ± 8.6 years, range 56 to 89 years) with newly diagnosed PCa undergoing 68Ga-PSMA-I&T PET/CT from June 2018 to July 2019. SUVmax and SUVmean of the primary lesions were measured, and the primary PSMA tumor volume (PSMA-TV) and total lesion PSMA (TL-PSMA) were automatically measured and calculated in all the patients. The correlations of primary SUVmax, PSMA-TV, and TL-PSMA with PSA and Gleason score (GS) were analyzed, and SUVmax, PSMA-TV and TL-PSMA of the primary lesions were compared among different PCa subgroups. RESULTS SUVmax, PSMA-TV and TL-PSMA of the primary lesions were all correlated with PSA and GS (P < 0.05). PCa subgroup analysis showed that SUVmax, PSMA-TV and TL-PSMA were all significantly higher in patients with PSA >20 ng/mL than in those with PSA ≤20 ng/mL (P < 0.001), and were higher in patients with a GS ≥8 than in those with a GS ≤7 (P < 0.001). PSMA-TV and TL-PSMA were significantly higher in patients with tumor metastasis than in those without metastasis (P < 0.001), while SUVmax did not differ significantly with tumor metastasis. SUVmax (P=0.002), PSMA-TV (P < 0.001), and TL-PSMA (P < 0.001) were all significantly higher in high-risk group than in low-to moderate-risk group. CONCLUSION PSMA-TV and TL-PSMA of 68Ga-PSMA-I&T PET/CT have potential value in predicting risk stratification and metastasis of newly diagnosed PCa.
Collapse
Affiliation(s)
- Y Xie
- Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.,Department of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.,Department of Nuclear Medicine, Zhongda Hospital, Southeast University, Nanjing 210009, China
| | - C Li
- Department of Nuclear Medicine, Zhongda Hospital, Southeast University, Nanjing 210009, China
| | - L Zhang
- Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China
| | - S Zang
- Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China
| | - F Yu
- Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China
| | - S Wang
- Department of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China
| | - F Wang
- Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China
| |
Collapse
|
33
|
Dai ZW, Yu F, Si MY, Wu YJ, Chen X, Fu JQ, Huang YM, Wang H, Xiao WJ, Mi GD, Su XY. [Influencing factors of suicidal ideation among men who have sex with men]. Zhonghua Liu Xing Bing Xue Za Zhi 2022; 43:1296-1300. [PMID: 35981993 DOI: 10.3760/cma.j.cn112338-20220311-00181] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Objective: To investigate the prevalence of suicidal ideation among MSM, and to explore the influence of perceived social support and depression on suicidal ideation and the possible pathway. Methods: MSM who are ≥18 years, HIV-negative, and ever had sex with men (oral sex/anal sex) in the last year participated in is study. Cross-sectional survey and convenient sampling method were used to recruit MSM through a male social interaction platform Blued 7.5 software from December 2020 to March 2021, with a questionnaire survey. Demographic questionnaire, Perceived Social Support Questionnaire and Center for Epidemiologic Studies Depression Scale were employed to collect data. Mplus 8.3 was used for data analysis. Results: Among 1 394 eligible MSM participants, 25.7% (358/1 394) had suicidal ideation. Perceived social support could have a direct effect on suicidal ideation (β=-0.11, P=0.009), and an indirect effect on suicidal ideation through depression (β=-0.18, P<0.001). Conclusions: Suicidal ideation was found to be lower in MSM with a higher level of perceived social support and a lower level of depression. Using social media to improve MSM's perceived social support and reduce depressive symptoms might be an effective means to prevent suicidal ideation.
Collapse
Affiliation(s)
- Z W Dai
- School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China
| | - F Yu
- Danlan Goodness, Beijing 100020, China
| | - M Y Si
- School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China
| | - Y J Wu
- School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China
| | - X Chen
- School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China
| | - J Q Fu
- School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China
| | - Y M Huang
- School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China
| | - H Wang
- School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China
| | - W J Xiao
- School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China
| | - G D Mi
- Danlan Goodness, Beijing 100020, China
| | - X Y Su
- School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China
| |
Collapse
|
34
|
Li JX, Huang YH, Yu F, Wang YY, Wang BH, Mao XH, Li J, Mo Z, Li LH. [Cladribine for the treatment with five male cases with xanthoma disseminatum]. Zhonghua Nei Ke Za Zhi 2022; 61:937-940. [PMID: 35922220 DOI: 10.3760/cma.j.cn112138-20210804-00528] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Affiliation(s)
- J X Li
- Department of Hematology and Oncology, Beijing Tsinghua Changgung Hospital affiliated to Tsinghua University, Beijing 102218, China
| | - Y H Huang
- Department of Hematology and Oncology, Beijing Tsinghua Changgung Hospital affiliated to Tsinghua University, Beijing 102218, China
| | - F Yu
- Department of Hematology and Oncology, Beijing Tsinghua Changgung Hospital affiliated to Tsinghua University, Beijing 102218, China
| | - Y Y Wang
- Department of Hematology and Oncology, Beijing Tsinghua Changgung Hospital affiliated to Tsinghua University, Beijing 102218, China
| | - B H Wang
- Department of Hematology and Oncology, Beijing Tsinghua Changgung Hospital affiliated to Tsinghua University, Beijing 102218, China
| | - X H Mao
- Department of Hematology and Oncology, Beijing Tsinghua Changgung Hospital affiliated to Tsinghua University, Beijing 102218, China
| | - J Li
- Department of Hematology and Oncology, Beijing Tsinghua Changgung Hospital affiliated to Tsinghua University, Beijing 102218, China
| | - Z Mo
- Department of Hematology and Oncology, Beijing Tsinghua Changgung Hospital affiliated to Tsinghua University, Beijing 102218, China
| | - L H Li
- Department of Hematology and Oncology, Beijing Tsinghua Changgung Hospital affiliated to Tsinghua University, Beijing 102218, China
| |
Collapse
|
35
|
He Y, Yu F, Tian Y, Hu Q, Wang B, Wang L, Hu Y, Tao Y, Chen X, Peng M. Single-Cell RNA Sequencing Unravels Distinct Tumor Microenvironment of Different Components of Lung Adenocarcinoma Featured as Mixed Ground-Glass Opacity. Front Immunol 2022; 13:903513. [PMID: 35874770 PMCID: PMC9299373 DOI: 10.3389/fimmu.2022.903513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2022] [Accepted: 06/01/2022] [Indexed: 11/21/2022] Open
Abstract
Lung adenocarcinoma featured as mixed ground-glass opacity (mGGO) doubled its volume half of the time in comparison with that featured as pure ground-glass opacity (pGGO). The mechanisms underlying the heterogeneous appearance of mGGO remain elusive. In this study, we macro-dissected the solid (S) components and ground-glass (GG) components of mGGO and performed single-cell sequencing analyses of six paired components from three mGGO patients. A total of 19,391 single-cell profiles were taken into analysis, and the data of each patient were analyzed independently to obtain a common alteration. Cancer cells and macrophages were the dominant cell types in the S and GG components, respectively. Cancer cells in the S components, which showed relatively malignant phenotypes, were likely to originate from both the GG and S components and monitor the surrounding tumor microenvironment (TME) through an intricate cell interaction network. SPP1hi macrophages were enriched in the S components and showed increased activity of chemoattraction, while macrophages in the GG components displayed an active antimicrobial process with a higher stress-induced state. In addition, the CD47–SIRPA axis was demonstrated to be critical in the maintenance of the GG components. Taken together, our study unraveled the alterations of cell components and transcriptomic features between different components in mGGOs.
Collapse
Affiliation(s)
- Yu He
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Fenglei Yu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Yi Tian
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.,Department of Thoracic Surgery, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China
| | - Qikang Hu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Bin Wang
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Li Wang
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Yan Hu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Yongguang Tao
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Xiaofeng Chen
- Department of Anaesthesia, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Muyun Peng
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
| |
Collapse
|
36
|
Hu Y, Ren S, Wang R, Han W, Xiao P, Wang L, Yu F, Liu W. Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable ALK-Positive Non-Small Cell Lung Cancer. Front Pharmacol 2022; 13:816683. [PMID: 35873553 PMCID: PMC9299059 DOI: 10.3389/fphar.2022.816683] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2021] [Accepted: 06/20/2022] [Indexed: 11/13/2022] Open
Abstract
Background: Alectinib, a highly selective inhibitor of ALK, is currently used in the first-line setting of untreated advanced ALK-positive NSCLC and in the second-line setting of crizotinib-resistant ALK-positive NSCLC. Despite promising efficacy and tolerability in the treatment of advanced ALK-positive NSCLC, the activity of alectinib as neoadjuvant therapy in resectable ALK-positive NSCLC remains to be investigated. Case presentation: Herein, we report a case of a 58-year-old female patient presented to our hospital with hemoptysis for 1 month. Contrast-enhanced computerized tomography (CT) of the chest showed an approximately 4.2 × 3.4 cm mass in the right hilum with localized obstructive pneumonia in the right lower lobe and multiple enlarged lymph nodes in the right hilum and mediastinum. Serum oncological markers results showed elevated levels of CA19-9, CEA, CA125, and CA242. Bronchoscopic biopsy of the mass showed poorly differentiated pulmonary adenocarcinoma and immunohistochemical testing results confirmed ALK positivity. Neoadjuvant alectinib was given at a dosage of 600 mg twice per day for two cycles (56 days), achieving a partial response of the disease with 90% shrinkage of the mass at the subsequent whole-body positron emission tomography. Repeat serum oncological markers results showed that only CA125 was elevated, but lower than before therapy. A bilobectomy of the right middle and lower lobes and systemic lymphadectomy under video-assisted thoracoscopic approach was successfully performed 7 days after the last dose of alectinib. Postoperative pathology showed pathological complete response (pCR). The patient experienced an uneventful postoperative course and continued to receive alectinib and did not report any specific discomfort at her 8-month follow-up. Thoracoabdominal CT at 8 months postoperatively showed no recurrence and repeated examination of serum oncological markers were negative. Conclusion: We report a case of resectable ALK-positive NSCLC treated with neoadjuvant aletinib achieving pCR. Our case highlights the feasibility of alectinib as neoadjuvant therapy for the treatment of resectable ALK-positive NSCLC. Undoubtedly, the safety and efficacy of this novel treatment modality needs to be explored in future large clinical trials.
Collapse
Affiliation(s)
- Yan Hu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Hunan Key Laboratory of Early Diagnosis and Precision Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Siying Ren
- Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital of Central South University, Research Unit of Respiratory Disease, Central South University, Hunan Diagnosis and Treatment Center of Respiratory Disease, Changsha, China
| | - Ruoyao Wang
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Hunan Key Laboratory of Early Diagnosis and Precision Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Wei Han
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Hunan Key Laboratory of Early Diagnosis and Precision Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Peng Xiao
- Department of Cardiothoracic Surgery, The Third Xiangya Hospital of Central South University, Changsha, China
| | - Li Wang
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Hunan Key Laboratory of Early Diagnosis and Precision Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Fenglei Yu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Hunan Key Laboratory of Early Diagnosis and Precision Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Wenliang Liu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Hunan Key Laboratory of Early Diagnosis and Precision Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| |
Collapse
|
37
|
Liang J, Yu F, Zhu J, Song T. [Impact of multi-leaf collimator positioning accuracy on quality control of volumetric modulation arc therapy plan for cervical cancer treated with Elekta linear accelerator]. Nan Fang Yi Ke Da Xue Xue Bao 2022; 42:1089-1094. [PMID: 35869775 DOI: 10.12122/j.issn.1673-4254.2022.07.19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
OBJECTIVE To investigate the influence of positioning accuracy of the multi-leaf collimators (MLC) on the passing rate of the plan dose verification for volumetric modulation arc therapy (VMAT) of cervical cancer using an Elekta linear accelerator. METHODS The dose distributions were measured using Sun Nuclear's Mapcheck and Arccheck semiconductors matrix before and after MLC calibration in30 cervical cancer patients undergoing VMAT. Dosimetric comparisons were performed with 2D and 3D gamma passing rates of 3%, 3 mm and 2%, and 2 mm. The 3D gamma distribution was reconstructed with respect to the patient's anatomy using 3DVH software to evaluate the possible influence of MLC positioning accuracy. RESULTS Before and after MLC calibration, the gamma passing rates of Mapcheck were (88.80±1.81)% and (99.25 ± 0.53)% under 3% and 3 mm standard, respectively, with an average increase of 10.45%. The corresponding gamma passing rates of Arccheck were (87.61±1.98)% and (98.13±0.99)%, respectively, with an average increase of 10.52%. The gamma passing rates of 3DVH were (89.87±2.28)% and (98.3±1.15)%, respectively, with an average increase of 8.43%. CONCLUSION The MLC positioning accuracy is one of the main factors influencing dosimetric accuracy of VMAT for cervical cancer. The application of Autocal software facilitates MLC calibration and improves the accuracy and safety of VMAT delivery for cervical cancer.
Collapse
Affiliation(s)
- J Liang
- School of Biomedical Engineering, Southern Medical University, Guangzhou 510515, China.,State Key Laboratory of Oncology in South China//Department of Radiotherapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
| | - F Yu
- State Key Laboratory of Oncology in South China//Department of Radiotherapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
| | - J Zhu
- State Key Laboratory of Oncology in South China//Department of Radiotherapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
| | - T Song
- School of Biomedical Engineering, Southern Medical University, Guangzhou 510515, China
| |
Collapse
|
38
|
Peng M, Yu F. Establishment of Thoracic Surgical Difficulty Assessment Scale based on Delphi method. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2022; 47:655-664. [PMID: 35753736 PMCID: PMC10929913 DOI: 10.11817/j.issn.1672-7347.2022.200782] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Received: 09/22/2020] [Indexed: 06/15/2023]
Abstract
OBJECTIVES The difficulty of surgery, which is related to surgical safety, has only been mentioned as a subjective perception for a long time. There are few studies to quantitatively and systematically evaluate the difficulty of thoracic surgery. This study aims to establish a quantitative evaluation index system for thoracic surgical difficulty, and to evaluate its reliability and validity. METHODS During the 2 national thoracic surgery academic conferences, the factors that may affect the difficulty of thoracic surgery were evaluated by the thoracic surgeons via semi open questionnaires, and then the evaluation item pool of thoracic surgery difficulty was established. The importance of each indicator in the evaluation item pool was graded by 2 rounds of Delphi method. The average score, full score rate and coefficient of variation of each index were calculated, and the composite index method was used to decide whether to delete the indicator.Finally, the difficulty evaluation scale of thoracic surgery was constructed. The surgical data of patients with thoracic tumors were collected. The scale was used to evaluate the difficulty of thoracic surgery for lung, esophageal, and mediastinal tumors. The reliability and validity of the scale were evaluated by the commonly used difficulty evaluation indexes: Operation time, intraoperative estimated blood loss, Visual Analog Scale (VAS), side injury rate, and blood transfusion rate as standards. RESULTS A total of 230 questionnaires were distributed in the 2 rounds of survey, and 149 valid questionnaires were collected after eliminating duplicate questionnaires. Through 2 rounds of Delphi consultation with 20 experts, the difficulty evaluation indexes were scored and screened, and the difficulty evaluation scale of thoracic surgery was established. It included 5 main indexes (surgical decision-making, operation space, separation interface, reconstruction method, and surgical materials) and 16 secondary indexes [American Society of Anesthesiologists (ASA) classification, surgical trauma, operator experience, space size, space depth, space source, space adjacent, interface content, anatomical gap, visual field, interface size, reconstruction complexity, reconstruction scope, autologous materials, artificial biomaterials and instruments]. After weighting, the total score of Thoracic Surgery Difficulty Evaluation Scale was from 1 to 3. A Score at 1 standed for simplicity, and score at 3 standed for difficulty. Further data were collected for 127 cases of thoracic tumor surgery. The difficulty scores of surgery for lung, esophageal, and mediastinal tumor were 1.69±0.26, 1.86±0.18, and 1.56±0.31, respectively, and the Cronbach's α coefficients of the scale in 3 tumor surgeries were 0.993, 0.974, and 0.989, repectively, and the Spearman Brown coefficients were 0.996, 0.984, and 0.996, respectively. The Spearman correlation coefficients of operation difficulty score with operation time, estimated blood loss, and VAS were 0.360 and 0.634, 0.632 and 0.578, 0.696 and 0.875, respectively (all P<0.05). The incidence of postoperative complications in the difficult operation group (difficulty score >1.85) was higher than that in the non-difficult operation group (P=0.02). CONCLUSIONS The quantitative Thoracic Surgical Difficulty Assessment Scale has been successfully established, which shows good reliability and validity in thoracic tumor surgery. The Thoracic Surgical Difficulty Assessment Scale has broad application prospects in reducing the difficulty of the surgery, controlling surgical complications, and training surgeons.
Collapse
Affiliation(s)
- Muyun Peng
- Department of Thoracic Surgery, Second Xiangya Hospital, Central South University, Changsha 410011, China.
| | - Fenglei Yu
- Department of Thoracic Surgery, Second Xiangya Hospital, Central South University, Changsha 410011, China.
| |
Collapse
|
39
|
Zhao Z, Yin W, Peng X, Cai Q, He B, Shi S, Peng W, Tu G, Li Y, Li D, Tao Y, Peng M, Wang X, Yu F. A Machine-Learning Approach to Developing a Predictive Signature Based on Transcriptome Profiling of Ground-Glass Opacities for Accurate Classification and Exploring the Immune Microenvironment of Early-Stage LUAD. Front Immunol 2022; 13:872387. [PMID: 35693786 PMCID: PMC9178173 DOI: 10.3389/fimmu.2022.872387] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2022] [Accepted: 04/27/2022] [Indexed: 11/13/2022] Open
Abstract
Screening for early-stage lung cancer with low-dose computed tomography is recommended for high-risk populations; consequently, the incidence of pure ground-glass opacity (pGGO) is increasing. Ground-glass opacity (GGO) is considered the appearance of early lung cancer, and there remains an unmet clinical need to understand the pathology of small GGO (<1 cm in diameter). The objective of this study was to use the transcriptome profiling of pGGO specimens <1 cm in diameter to construct a pGGO-related gene risk signature to predict the prognosis of early-stage lung adenocarcinoma (LUAD) and explore the immune microenvironment of GGO. pGGO-related differentially expressed genes (DEGs) were screened to identify prognostic marker genes with two machine learning algorithms. A 15-gene risk signature was constructed from the DEGs that were shared between the algorithms. Risk scores were calculated using the regression coefficients for the pGGO-related DEGs. Patients with Stage I/II LUAD or Stage IA LUAD and high-risk scores had a worse prognosis than patients with low-risk scores. The prognosis of high-risk patients with Stage IA LUAD was almost identical to that of patients with Stage II LUAD, suggesting that treatment strategies for patients with Stage II LUAD may be beneficial in high-risk patients with Stage IA LUAD. pGGO-related DEGs were mainly enriched in immune-related pathways. Patients with high-risk scores and high tumor mutation burden had a worse prognosis and may benefit from immunotherapy. A nomogram was constructed to facilitate the clinical application of the 15-gene risk signature. Receiver operating characteristic curves and decision curve analysis validated the predictive ability of the nomogram in patients with Stage I LUAD in the TCGA-LUAD cohort and GEO datasets.
Collapse
Affiliation(s)
- Zhenyu Zhao
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Wei Yin
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Xiong Peng
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Qidong Cai
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Boxue He
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Shuai Shi
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Weilin Peng
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Guangxu Tu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Yunping Li
- Department of Ophthalmology, The Second Xiangya Hospital of Central South University, Changsha, China
| | | | - Yongguang Tao
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
- Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Department of Pathology, Xiangya Hospital, Central South University, Changsha, China
- National Health Council (NHC) Key Laboratory of Carcinogenesis (Central South University), Cancer Research Institute and School of Basic Medicine, Central South University, Changsha, China
| | - Muyun Peng
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
- *Correspondence: Xiang Wang, ; Muyun Peng, ; Fenglei Yu,
| | - Xiang Wang
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
- *Correspondence: Xiang Wang, ; Muyun Peng, ; Fenglei Yu,
| | - Fenglei Yu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
- *Correspondence: Xiang Wang, ; Muyun Peng, ; Fenglei Yu,
| |
Collapse
|
40
|
Wang C, Hu Q, Sun Y, Yu F, Peng M. Complete pathological remission after neoadjuvant ensartinib in patients with locally advanced lung adenocarcinoma and with CTLC-ALK and ALK-DHX8 rearrangements. Eur J Cancer 2022; 169:131-134. [PMID: 35567918 DOI: 10.1016/j.ejca.2022.04.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2022] [Accepted: 04/04/2022] [Indexed: 11/03/2022]
Affiliation(s)
- Cheng Wang
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Qikang Hu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China; Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China; Early-Stage Lung Cancer Center, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Yi Sun
- Department of Pathology, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Fenglei Yu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China; Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China; Early-Stage Lung Cancer Center, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Muyun Peng
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China; Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China; Early-Stage Lung Cancer Center, The Second Xiangya Hospital of Central South University, Changsha, China.
| |
Collapse
|
41
|
Hu Y, Ren S, Yang L, Tong Z, Wang R, Han W, Zeng C, Li J, Xiao P, Wang L, Yu F, Liu W. Osimertinib as Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: A Case Series. Front Pharmacol 2022; 13:912153. [PMID: 35571073 PMCID: PMC9096023 DOI: 10.3389/fphar.2022.912153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2022] [Accepted: 04/18/2022] [Indexed: 11/13/2022] Open
Abstract
Background: Evidence of osimertinib as neoadjuvant therapy for resectable non-small cell lung cancer (NSCLC) are currently lacking. This case series study aimed to assess the safety and feasibility of neoadjuvant osimertinib therapy followed by surgery for resectable NSCLC.Materials and methods: Patients with resectable NSCLC with epidermal growth factor receptor (EGFR) mutation who received osimertinib as neoadjuvant therapy followed by surgery at our center were included. Demographic features, radiologic and pathological assessment of response, surgery-related details and complications, toxicity profiles, and prognostic outcomes were extracted.Results: A total of 13 patients were included in this study. The median age at the time of surgical resection was 57 years (interquartile range: 52–64 years), and eight (61.5%) patients were female. The objective response rate (ORR) was 69.2% (9/13), and the complete resection rate was 100%. The rates of pathologic downstaging and lymph node downstaging were 100% (13/13) and 66.7% (6/9), respectively. There were no perioperative deaths and only three (23.1%) patients had postoperative complications. Seven (53.8%) and 13 (100%) patients experienced grade 1 treatment-related adverse reactions and laboratory abnormalities, respectively. No patients experienced drug withdrawal or surgical delays due to the adverse events. No patients showed grade 2 or worse toxicity profiles. One patient was lost to follow-up. The other 12 patients were alive and free of disease recurrence with a median follow-up time of 9.5 months.Conclusion: Neoadjuvant osimertinib therapy seemed to be safe and feasible for resectable EGFR-mutated NSCLC. Future large prospective studies are warranted to confirm whether osimertinib as neoadjuvant therapy outperforms standard tyrosine kinase inhibitors (TKIs) or chemotherapy for resectable EGFR-mutated NSCLC.
Collapse
Affiliation(s)
- Yan Hu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
- Hunan Key Laboratory of Early Diagnosis and Precision Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Siying Ren
- Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital of Central South University, Changsha, China
- Research Unit of Respiratory Disease, Central South University, Changsha, China
- Hunan Diagnosis and Treatment Center of Respiratory Disease, Changsha, China
| | - Lulu Yang
- Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital of Central South University, Changsha, China
- Research Unit of Respiratory Disease, Central South University, Changsha, China
- Hunan Diagnosis and Treatment Center of Respiratory Disease, Changsha, China
| | - Zhongyi Tong
- Department of Pathology, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Ruoyao Wang
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
- Hunan Key Laboratory of Early Diagnosis and Precision Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Wei Han
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
- Hunan Key Laboratory of Early Diagnosis and Precision Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Chao Zeng
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
- Hunan Key Laboratory of Early Diagnosis and Precision Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Jina Li
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
- Hunan Key Laboratory of Early Diagnosis and Precision Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Peng Xiao
- Department of Cardiothoracic Surgery, The Third Xiangya Hospital of Central South University, Changsha, China
| | - Li Wang
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
- Hunan Key Laboratory of Early Diagnosis and Precision Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Fenglei Yu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
- Hunan Key Laboratory of Early Diagnosis and Precision Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Wenliang Liu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
- Hunan Key Laboratory of Early Diagnosis and Precision Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
- *Correspondence: Wenliang Liu,
| |
Collapse
|
42
|
Yao XC, Zhang C, Zang SM, Zhang PJ, Wang J, Xu L, Yu F, Gao XJ, Tang QY, Wang F. [Efficiency and safety of peptide receptor radionuclide therapy in the treatment of metastatic neuroendocrine tumors]. Zhonghua Yi Xue Za Zhi 2022; 102:1034-1038. [PMID: 35399024 DOI: 10.3760/cma.j.cn112137-20211223-02872] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The clinical data of 14 patients with neuroendocrine tumors who received Peptide Receptor Radionuclide Therapy (PRRT) from December 2018 to May 2021 were retrospectively analyzed. Among them, 2 patients demonstrated proprogressive disease, 2 patients had partial response, and 10 patients had stable disease. Grade 1-2 myelosuppression occurred in 5 patients. and 1 patient became grade 3 myelosuppression,which recovered to grade 2 after symptomatic treatment. No grade 2 or higher treatment-related renal toxicity was observed in any of the patients. PRRT is efficacy and no significant side effects for unresectable metastatic neuroendocrine tumors.
Collapse
Affiliation(s)
- X C Yao
- Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China
| | - C Zhang
- Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China
| | - S M Zang
- Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China
| | - P J Zhang
- Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China
| | - J Wang
- Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China
| | - L Xu
- Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China
| | - F Yu
- Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China
| | - X J Gao
- Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China
| | - Q Y Tang
- Institution of Neuroendocrinology, Nanjing Medical University, Nanjing 210000, China
| | - F Wang
- Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China
| |
Collapse
|
43
|
Zhang R, Dong TL, Liang WL, Cao ZB, Xie Z, Liu KM, Yu F, Fu GF, Zhang YQ, Wang GY, Ma QQ, Wu SB, Li Y, Dong W, Jiang Z, Xu J, Wu ZY, Yao J, Pan PL, Qiu MF. [Analysis of HIV-1 genetic subtype and pretreatment drug resistance among men who have sex with men infected with HIV-1 from 19 cities of 6 provinces in China]. Zhonghua Liu Xing Bing Xue Za Zhi 2022; 43:523-527. [PMID: 35443307 DOI: 10.3760/cma.j.cn112338-20211125-00918] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Objective: To investigate the distribution of HIV-1 genetic subtypes and pretreatment drug resistance (PDR) among men who have sex with men (MSM) from 19 cities of 6 provinces in China. Methods: From April to November 2019, 574 plasma samples of ART-naive HIV-1 infected MSM were collected from 19 cities in Hebei, Shandong, Jiangsu, Zhejiang, Fujian, and Guangdong provinces, total ribonucleic acid (RNA) was extracted and amplified the HIV-1 pol gene region by nested polymerase chain reaction (PCR) after reverse transcription. Then sequences were used to construct a phylogenetic tree to determine genetic subtypes and submitted to the Stanford drug resistance database for drug resistance analysis. Results: A total of 479 samples were successfully amplified by PCR. The HIV-1 genetic subtypes included CRF01_AE, CRF07_BC, B, CRF55_01B, CRF59_01B, CRF65_cpx, CRF103_01B, CRF67_01B, CRF68_01B and unrecognized subtype, which accounted for 43.4%, 36.3%, 6.3%, 5.9%, 0.8%, 0.8%, 0.4%, 0.4%, 0.2% and 5.5%, respectively. The distribution of genetic subtypes among provinces is statistically different (χ2=44.141, P<0.001). The overall PDR rate was 4.6% (22/479), the drug resistance rate of non-nucleoside reverse transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, and protease inhibitors were 3.5% (17/479), 0.8% (4/479) and 0.2% (1/479), respectively. The PDR rate of recent infections was significantly higher than that of long-term infections (χ2=4.634, P=0.031). Conclusions: The HIV-1 genetic subtypes among MSM infected with HIV-1 from 19 cities of 6 provinces in China are diverse, and the distribution of subtypes is different among provinces. The overall PDR rate is low, while the PDR rate of recent infections was significantly higher than that of long-term infections, suggesting the surveillance of PDR in recent infections should be strengthened.
Collapse
Affiliation(s)
- R Zhang
- National HIV Reference Laboratory, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - T L Dong
- Division of HIV Prevention and Intervention, National Center for AIDS/STD Control and Prevention,Chinese Center for Disease Control and Prevention, Beijing 102206,China
| | - W L Liang
- National HIV Reference Laboratory, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - Z B Cao
- Division of HIV Prevention and Intervention, National Center for AIDS/STD Control and Prevention,Chinese Center for Disease Control and Prevention, Beijing 102206,China
| | - Z Xie
- Division of HIV Prevention and Intervention, National Center for AIDS/STD Control and Prevention,Chinese Center for Disease Control and Prevention, Beijing 102206,China
| | - K M Liu
- Division of HIV Prevention and Intervention, National Center for AIDS/STD Control and Prevention,Chinese Center for Disease Control and Prevention, Beijing 102206,China
| | - F Yu
- Danlan Beijing Media Limited, Beijing 100020, China
| | - G F Fu
- Jiangsu Provincial Center for Disease Control and Prevention,Nanjing 210009, China
| | - Y Q Zhang
- Hebei Provincial Center for Disease Control and Prevention,Shijiazhuang 050021, China
| | - G Y Wang
- Shandong Center for Disease Control and Prevention, Ji'nan 250014, China
| | - Q Q Ma
- Zhejiang Provincial Center for Disease Control and Prevention,Hangzhou 310051, China
| | - S B Wu
- Fujian Provincial Center for Disease Control and Prevention, Fuzhou 350012,China
| | - Y Li
- Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, China
| | - W Dong
- Division of HIV Prevention and Intervention, National Center for AIDS/STD Control and Prevention,Chinese Center for Disease Control and Prevention, Beijing 102206,China
| | - Z Jiang
- Division of HIV Prevention and Intervention, National Center for AIDS/STD Control and Prevention,Chinese Center for Disease Control and Prevention, Beijing 102206,China
| | - J Xu
- Division of HIV Prevention and Intervention, National Center for AIDS/STD Control and Prevention,Chinese Center for Disease Control and Prevention, Beijing 102206,China
| | - Z Y Wu
- Division of HIV Prevention and Intervention, National Center for AIDS/STD Control and Prevention,Chinese Center for Disease Control and Prevention, Beijing 102206,China
| | - J Yao
- National HIV Reference Laboratory, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - P L Pan
- National HIV Reference Laboratory, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - M F Qiu
- National HIV Reference Laboratory, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| |
Collapse
|
44
|
Yu F, Yang HJ, Wang ZM, Yu WJ. [T-cell lymphoblastic lymphoma as the initial presentation of myeloid/lymphoid neoplasm with PDGFRA rearrangement: report of a case]. Zhonghua Bing Li Xue Za Zhi 2022; 51:357-359. [PMID: 35359051 DOI: 10.3760/cma.j.cn112151-20210815-00570] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Affiliation(s)
- F Yu
- Department of Pathology, the First Affiliated Hospital of Zhejiang University, Hangzhou 310016,China
| | - H J Yang
- Department of Pathology, the First Affiliated Hospital of Zhejiang University, Hangzhou 310016,China
| | - Z M Wang
- Department of Pathology, the First Affiliated Hospital of Zhejiang University, Hangzhou 310016,China
| | - W J Yu
- Department of Hematology, the First Affiliated Hospital of Zhejiang University, Hangzhou 310016,China
| |
Collapse
|
45
|
Ma C, Li H, Zhang T, Wei Y, Zhang H, Yu F, Lv Y, Ren Y. Comparison of Percutaneous Endoscopic Interlaminar Discectomy and Open Fenestration Discectomy for Single-Segment Huge Lumbar Disc Herniation: A Two-year Follow-up Retrospective Study. J Pain Res 2022; 15:1061-1070. [PMID: 35444463 PMCID: PMC9013921 DOI: 10.2147/jpr.s352595] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2021] [Accepted: 04/06/2022] [Indexed: 01/18/2023] Open
Abstract
Purpose Both percutaneous endoscopic lumbar discectomy (PELD) and open fenestration discectomy (OFD) are effective and safe surgical procedures for the treatment of LDH. The purpose of this retrospective study was to compare the surgical outcomes of percutaneous endoscopic interlaminar discectomy (PEID) and OFD for single-segment huge lumbar disc herniation (HLDH). Patients and Methods We retrospectively analyzed 91 patients diagnosed with single-segment HLDH and treated with OFD or PEID. Visual analog scale (VAS), modified Japanese orthopedic association (mJOA) and Oswestry disability index (ODI) were used to assess clinical outcomes at preoperation and postoperatively at 3, 6, 12, and 24months. Modified Macnab criteria were applied to evaluate clinically satisfaction at the final follow-up. Results In both groups, the VAS and ODI scores at 3, 6, 12, and 24months postoperatively showed a significant decrease and the mJOA score at 3, 6, 12, and 24months postoperatively was significantly increased compared to preoperative results (P<0.001). According to Macnab criteria at the final follow-up, the overall clinically satisfactory rate was 86.67% in the OFD group and 86.96% in the PEID group. There were no significant differences in VAS, ODI, and mJOA scores between the two groups at preoperation and postoperative 3, 6, 12, and 24months, respectively. In the PEID group, the length of hospitalization and the length of incision were significantly shorter than that in the OFD group (P<0.0001). However, there was no significant difference in operative time between groups (P=0.81). Conclusion Collectively, postoperative clinical results were equally favorable for both procedures, with no statistically significant difference between PEID and OFD at the two-year of follow-up. No serious complication was observed in two groups. Compared with the traditional surgery, PEID has the following benefits: less trauma, less bleeding, speedy recovery, and shorter hospitalization. Therefore, PEID may be a promising alternative to traditional surgery.
Collapse
Affiliation(s)
- Cheng Ma
- Department of Orthopaedics, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, Jiangsu, People’s Republic of China
| | - He Li
- Department of Orthopaedics, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, Jiangsu, People’s Republic of China
| | - Teng Zhang
- Department of Orthopaedics, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, Jiangsu, People’s Republic of China
| | - Yifan Wei
- Department of Orthopaedics, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, Jiangsu, People’s Republic of China
| | - Helong Zhang
- Department of Orthopaedics, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, Jiangsu, People’s Republic of China
| | - Fenglei Yu
- Department of Orthopaedics, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, Jiangsu, People’s Republic of China
| | - You Lv
- Department of Orthopaedics, Lianyungang Clinical College of Nanjing Medical University, The First People’s Hospital of Lianyungang, Lianyungang, 222061, Jiangsu, People’s Republic of China
| | - Yongxin Ren
- Department of Orthopaedics, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, Jiangsu, People’s Republic of China
- Correspondence: Yongxin Ren, Tel +86 13585162283, Email
| |
Collapse
|
46
|
Peng W, Li B, Li J, Chang L, Bai J, Yi Y, Chen R, Zhang Y, Chen C, Pu X, Jiang M, Li J, Zhong R, Xu F, Chen B, Xu L, Wang N, Huan J, Dai P, Guan Y, Yang L, Xia X, Yi X, Wang J, Yu F, Wu L. Clinical and genomic features of Chinese lung cancer patients with germline mutations. Nat Commun 2022; 13:1268. [PMID: 35273153 PMCID: PMC8913621 DOI: 10.1038/s41467-022-28840-5] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2019] [Accepted: 02/08/2022] [Indexed: 12/12/2022] Open
Abstract
The germline mutation landscape in Chinese lung cancer patients has not been well defined. In this study, sequencing data of 1,021 cancer genes of 1,794 Chinese lung cancer patients was analyzed. A total of 111 pathogenic or likely pathogenic germline mutations were identified, significantly higher than non-cancer individuals (111/1794 vs. 84/10,588, p < 2.2e-16). BRCA1/2 germline mutations are associated with earlier onset age (median 52.5 vs 60 years-old, p = 0.008). Among 29 cancer disposition genes with germline mutations detected in Chinese cohort and/or TCGA lung cancer cohort, Only 11 from 29 genes are identified in both cohorts and BRCA2 mutations are significantly more common in Chinese cohort (p = 0.015). Chinese patients with germline mutations have different prevalence of somatic KRAS, MET exon 14 skipping and TP53 mutations compared to those without. Our findings suggest potential ethnic and etiologic differences between Western and Asian lung cancer patients.
Collapse
Affiliation(s)
- Wenying Peng
- The Second Department of Thoracic Oncology, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, 410000, Changsha, China.,The second department of Oncology, Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center, 650000, Kunming, China
| | - Bin Li
- Department of Oncology, Xiangya Hospital, Central South University, 410000, Changsha, China.,National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, 410000, Changsha, China
| | - Jin Li
- Geneplus-Beijing, 103306, Beijing, China
| | | | - Jing Bai
- Geneplus-Beijing, 103306, Beijing, China
| | - Yuting Yi
- Geneplus-Beijing, 103306, Beijing, China
| | | | | | - Chen Chen
- Geneplus-Beijing, 103306, Beijing, China
| | - Xingxiang Pu
- The Second Department of Thoracic Oncology, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, 410000, Changsha, China
| | - Meilin Jiang
- The Second Department of Thoracic Oncology, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, 410000, Changsha, China
| | - Jia Li
- The Second Department of Thoracic Oncology, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, 410000, Changsha, China
| | - Rui Zhong
- The Second Department of Thoracic Oncology, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, 410000, Changsha, China
| | - Fang Xu
- The Second Department of Thoracic Oncology, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, 410000, Changsha, China
| | - Bolin Chen
- The Second Department of Thoracic Oncology, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, 410000, Changsha, China
| | - Li Xu
- The Second Department of Thoracic Oncology, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, 410000, Changsha, China
| | - Ning Wang
- Department of Oncology, The PLA Rocket Force Characteristic Medical Center, 100088, Beijing, China
| | | | | | | | - Ling Yang
- Geneplus-Beijing, 103306, Beijing, China
| | | | - Xin Yi
- Geneplus-Beijing, 103306, Beijing, China
| | - Jiayin Wang
- Department of Computer Science and Technology, School of Electronic and Information Engineering, Xi'an Jiaotong University, 710049, Xi'an, China
| | - Fenglei Yu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, 410000, Changsha, China.
| | - Lin Wu
- The Second Department of Thoracic Oncology, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, 410000, Changsha, China.
| |
Collapse
|
47
|
Yu H, Liu J, Liao Z, Yu F, Qiu B, Zhou M, Li F, Chen J, Zhou W, Zhang L. Location of MMPs in human radicular dentin and the effects of MMPs inhibitor on the bonding stability of fiber posts to radicular dentin. J Mech Behav Biomed Mater 2022; 129:105144. [DOI: 10.1016/j.jmbbm.2022.105144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2022] [Revised: 02/22/2022] [Accepted: 02/23/2022] [Indexed: 11/16/2022]
|
48
|
Zhao Z, Qian B, Peng X, Yin W, Cai Q, Zhang P, He B, Shi S, Peng W, Tu G, Tao Y, Wang X, Yu F, Li Y. Metagenomic analysis of the microbiome of lung adenocarcinoma with pure ground‐glass opacity. Clin Transl Med 2022; 12:e698. [PMID: 35060677 PMCID: PMC8778636 DOI: 10.1002/ctm2.698] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2021] [Revised: 12/11/2021] [Accepted: 12/20/2021] [Indexed: 11/23/2022] Open
Affiliation(s)
- Zhenyu Zhao
- Department of Thoracic Surgery The Second Xiangya Hospital of Central South University Changsha China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer The Second Xiangya Hospital of Central South University Changsha China
| | - Banglun Qian
- Department of Thoracic Surgery The Second Xiangya Hospital of Central South University Changsha China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer The Second Xiangya Hospital of Central South University Changsha China
| | - Xiong Peng
- Department of Thoracic Surgery The Second Xiangya Hospital of Central South University Changsha China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer The Second Xiangya Hospital of Central South University Changsha China
| | - Wei Yin
- Department of Thoracic Surgery The Second Xiangya Hospital of Central South University Changsha China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer The Second Xiangya Hospital of Central South University Changsha China
| | - Qidong Cai
- Department of Thoracic Surgery The Second Xiangya Hospital of Central South University Changsha China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer The Second Xiangya Hospital of Central South University Changsha China
| | - Pengfei Zhang
- Department of Thoracic Surgery The Second Xiangya Hospital of Central South University Changsha China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer The Second Xiangya Hospital of Central South University Changsha China
| | - Boxue He
- Department of Thoracic Surgery The Second Xiangya Hospital of Central South University Changsha China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer The Second Xiangya Hospital of Central South University Changsha China
| | - Shuai Shi
- Department of Thoracic Surgery The Second Xiangya Hospital of Central South University Changsha China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer The Second Xiangya Hospital of Central South University Changsha China
| | - Weilin Peng
- Department of Thoracic Surgery The Second Xiangya Hospital of Central South University Changsha China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer The Second Xiangya Hospital of Central South University Changsha China
| | - Guangxu Tu
- Department of Thoracic Surgery The Second Xiangya Hospital of Central South University Changsha China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer The Second Xiangya Hospital of Central South University Changsha China
| | - Yongguang Tao
- Department of Thoracic Surgery The Second Xiangya Hospital of Central South University Changsha China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer The Second Xiangya Hospital of Central South University Changsha China
- Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Department of Pathology, Xiangya Hospital Central South University Changsha China
- NHC Key Laboratory of Carcinogenesis (Central South University) Cancer Research Institute and School of Basic Medicine Central South University Changsha China
| | - Xiang Wang
- Department of Thoracic Surgery The Second Xiangya Hospital of Central South University Changsha China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer The Second Xiangya Hospital of Central South University Changsha China
| | - Fenglei Yu
- Department of Thoracic Surgery The Second Xiangya Hospital of Central South University Changsha China
- Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer The Second Xiangya Hospital of Central South University Changsha China
| | - Yunping Li
- Department of Ophthalmology The Second Xiangya Hospital of Central South University Changsha China
| |
Collapse
|
49
|
Hu Y, Chen X, Ren S, Zeng C, Wang L, Xiao P, Yu F, Liu W. Case Report: Uniportal Video-Assisted Thoracoscopic Parenchymal Sparing Secondary Carinal Resection and Reconstruction for the Treatment of Tracheobronchial Mucoepidermoid Carcinoma. Front Surg 2022; 8:823281. [PMID: 35118115 PMCID: PMC8803630 DOI: 10.3389/fsurg.2021.823281] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2021] [Accepted: 12/27/2021] [Indexed: 11/13/2022] Open
Abstract
Surgical resection is currently the mainstay of treatment for tracheobronchial mucoepidermoid carcinoma (TMEC). The parenchymal sparing secondary carinal resection and reconstruction for TMEC under the uniportal thoracoscopic approach has seldomly been reported in the literature. Here, we report a case of a 42-year-old male patient complaining of the incidental finding of a 1.5 × 1.2 cm neoplasm at the opening of the right bronchus intermedius and a 5.1 × 3.1 cm patchy lesion located at the left upper lobe by chest CT scans in February 2021. This patient successively underwent fiberoptic bronchoscopic biopsy of the bronchial neoplasm and CT-guided biopsy of the left upper lobe lesion. Pathological examination confirmed the diagnosis of the endobronchial mass in the right bronchus intermedius as low-grade mucoepidermoid carcinoma and left upper lobe lesion as tuberculosis. This patient successfully underwent uniportal thoracoscopic parenchymal sparing tumor resection, reconstruction of the secondary carina and lymphadenectomy at our center. Intraoperative frozen section showed no residual cancer at any bronchial stumps. Postoperative pathology indicated that no metastases were seen in any of the resected lymph nodes. The patient recovered well after surgery. He received a 9-month course of anti-tuberculosis treatment postoperatively. He did not complain of any special discomfort and there was no local recurrence at the 9-month postoperative follow-up. Although technical demanding, this case highlights that uniportal video-assisted thoracoscopic parenchymal sparing secondary carinal resection and reconstruction for TMEC is safe and feasible with the preservation of lung function and excellent outcomes.
Collapse
Affiliation(s)
- Yan Hu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
- Hunan Key Laboratory of Early Diagnosis and Precision Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Xiaofeng Chen
- Department of Anesthesia, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Siying Ren
- Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Chao Zeng
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
- Hunan Key Laboratory of Early Diagnosis and Precision Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Li Wang
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
- Hunan Key Laboratory of Early Diagnosis and Precision Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Peng Xiao
- Department of Cardiothoracic Surgery, The Third Xiangya Hospital of Central South University, Changsha, China
| | - Fenglei Yu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
- Hunan Key Laboratory of Early Diagnosis and Precision Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Wenliang Liu
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China
- Hunan Key Laboratory of Early Diagnosis and Precision Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China
- *Correspondence: Wenliang Liu
| |
Collapse
|
50
|
Tang XJ, Duan LJ, Liang WL, Cheng S, Dong TL, Xie Z, Liu KM, Yu F, Chen ZH, Mi GD, Liang L, Yan HJ, Chen L, Lin L, Kang DM, Fu XB, Qiu MF, Jiang Z, Xu ZY, Wu Z. [Application of limiting antigen avidity enzyme immunoassay for estimating HIV-1 incidence in men who have sex with men]. Zhonghua Liu Xing Bing Xue Za Zhi 2022; 43:72-77. [PMID: 35130655 DOI: 10.3760/cma.j.cn112338-20210609-00463] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Objective: To estimate the incidence of HIV-1 infection in men who have sex with men (MSM) in key areas of China through HIV-1 limiting antigen avidity enzyme immunoassay (LAg-Avidity EIA), analyze the deviation from the actual results and identify influencing factors, and provided reference for improving the accuracy of estimation results. Methods: Based on the principle of the cohort randomized study design, 20 cities were selected in China based on population size and the number of HIV-positive MSM. The sample size was estimated to be 700 according to the HIV-1 infection rate in MSM. MSM mobile phone app. was used to establish a detection appointment and questionnaire system, and the baseline cross-sectional survey was conducted from April to November 2019. LAg-Avidity EIA was used to identify the recent infected samples. The incidence of HIV-1 infection was calculated and then adjusted based on the estimation formula designed by WHO. The influencing factors were identified by analyzing the sample collection and detection processes. Results: Among the 10 650 blood samples from the participants, 799 were HIV-positive in initial screening, in which 198 samples (24.78%) missed during confirmation test. Only 621 samples were received by the laboratory. After excluding misreported samples, 520 samples were qualified for testing. A total of 155 samples were eventually determined as recent infection through LAg-Avidity EIA; Based on the estimation formula , the incidence of HIV-1 infection in MSM in 20 cities was 4.06% (95%CI:3.27%-4.85%), it increased to 5.53% (95%CI: 4.45%-6.60%)after the adjusting for sample missing rate. When the sample missing rate and misreporting rate were both adjusted, the incidence of HIV-1 infection in the MSM increased to 5.66% (95%CI:4.67%-6.65%). The actual incidence of HIV-1 infection in MSM in the 20 cities might be between 4.06% and 5.66%. Conclusions: Sample missing and misreporting might cause the deviation of the estimation of HIV-1 infection incidence. It is important to ensure the sample source and the quality of sample collection and detection to reduce the deviation in the estimation of HIV-1 infection incidence.
Collapse
Affiliation(s)
- X J Tang
- Division of Prevention and Intervention, National Center for AIDS and STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - L J Duan
- National HIV/AIDS Reference Laboratory, National Center for AIDS and STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - W L Liang
- National HIV/AIDS Reference Laboratory, National Center for AIDS and STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - S Cheng
- Division of Prevention and Intervention, National Center for AIDS and STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - T L Dong
- Division of Prevention and Intervention, National Center for AIDS and STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - Z Xie
- Division of Prevention and Intervention, National Center for AIDS and STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - K M Liu
- Division of Prevention and Intervention, National Center for AIDS and STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - F Yu
- Danlan Beijing Media Limited, Beijing 100020, China
| | - Z H Chen
- Danlan Beijing Media Limited, Beijing 100020, China
| | - G D Mi
- Danlan Beijing Media Limited, Beijing 100020, China
| | - L Liang
- Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang 050021, China
| | - H J Yan
- Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China
| | - L Chen
- Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, China
| | - L Lin
- Fujian Provincial Center for Disease Control and Prevention, Fuzhou 350001, China
| | - D M Kang
- Shandong Provincial Center for Disease Control and Prevention, Ji'nan 250014, China
| | - X B Fu
- Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, China
| | - M F Qiu
- National HIV/AIDS Reference Laboratory, National Center for AIDS and STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - Z Jiang
- Division of Prevention and Intervention, National Center for AIDS and STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - Z Y Xu
- Division of Prevention and Intervention, National Center for AIDS and STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - Zunyou Wu
- Division of Prevention and Intervention, National Center for AIDS and STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| |
Collapse
|